CA2432159A1 - Medicated polymer-coated stent assembly - Google Patents
Medicated polymer-coated stent assembly Download PDFInfo
- Publication number
- CA2432159A1 CA2432159A1 CA002432159A CA2432159A CA2432159A1 CA 2432159 A1 CA2432159 A1 CA 2432159A1 CA 002432159 A CA002432159 A CA 002432159A CA 2432159 A CA2432159 A CA 2432159A CA 2432159 A1 CA2432159 A1 CA 2432159A1
- Authority
- CA
- Canada
- Prior art keywords
- polymer
- coat
- pharmaceutical agent
- liquefied polymer
- stent assembly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/507—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials for artificial blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C67/00—Shaping techniques not covered by groups B29C39/00 - B29C65/00, B29C70/00 or B29C73/00
- B29C67/20—Shaping techniques not covered by groups B29C39/00 - B29C65/00, B29C70/00 or B29C73/00 for porous or cellular articles, e.g. of foam plastics, coarse-pored
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01D—MECHANICAL METHODS OR APPARATUS IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS
- D01D5/00—Formation of filaments, threads, or the like
- D01D5/0007—Electro-spinning
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01D—MECHANICAL METHODS OR APPARATUS IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS
- D01D5/00—Formation of filaments, threads, or the like
- D01D5/0007—Electro-spinning
- D01D5/0061—Electro-spinning characterised by the electro-spinning apparatus
- D01D5/0069—Electro-spinning characterised by the electro-spinning apparatus characterised by the spinning section, e.g. capillary tube, protrusion or pin
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01D—MECHANICAL METHODS OR APPARATUS IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS
- D01D5/00—Formation of filaments, threads, or the like
- D01D5/0007—Electro-spinning
- D01D5/0061—Electro-spinning characterised by the electro-spinning apparatus
- D01D5/0092—Electro-spinning characterised by the electro-spinning apparatus characterised by the electrical field, e.g. combined with a magnetic fields, using biased or alternating fields
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01D—MECHANICAL METHODS OR APPARATUS IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS
- D01D5/00—Formation of filaments, threads, or the like
- D01D5/18—Formation of filaments, threads, or the like by means of rotating spinnerets
-
- D—TEXTILES; PAPER
- D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
- D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
- D04H1/00—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres
- D04H1/70—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres characterised by the method of forming fleeces or layers, e.g. reorientation of fibres
- D04H1/72—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres characterised by the method of forming fleeces or layers, e.g. reorientation of fibres the fibres being randomly arranged
- D04H1/728—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres characterised by the method of forming fleeces or layers, e.g. reorientation of fibres the fibres being randomly arranged by electro-spinning
-
- D—TEXTILES; PAPER
- D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
- D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
- D04H3/00—Non-woven fabrics formed wholly or mainly of yarns or like filamentary material of substantial length
- D04H3/02—Non-woven fabrics formed wholly or mainly of yarns or like filamentary material of substantial length characterised by the method of forming fleeces or layers, e.g. reorientation of yarns or filaments
- D04H3/07—Non-woven fabrics formed wholly or mainly of yarns or like filamentary material of substantial length characterised by the method of forming fleeces or layers, e.g. reorientation of yarns or filaments otherwise than in a plane, e.g. in a tubular way
-
- D—TEXTILES; PAPER
- D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
- D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
- D04H3/00—Non-woven fabrics formed wholly or mainly of yarns or like filamentary material of substantial length
- D04H3/08—Non-woven fabrics formed wholly or mainly of yarns or like filamentary material of substantial length characterised by the method of strengthening or consolidating
- D04H3/16—Non-woven fabrics formed wholly or mainly of yarns or like filamentary material of substantial length characterised by the method of strengthening or consolidating with bonds between thermoplastic filaments produced in association with filament formation, e.g. immediately following extrusion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
- A61F2/07—Stent-grafts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
- A61F2/07—Stent-grafts
- A61F2002/072—Encapsulated stents, e.g. wire or whole stent embedded in lining
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0076—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof multilayered, e.g. laminated structures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0014—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
- A61F2250/0023—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in porosity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]
- Y10T428/1352—Polymer or resin containing [i.e., natural or synthetic]
- Y10T428/1372—Randomly noninterengaged or randomly contacting fibers, filaments, particles, or flakes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]
- Y10T428/1352—Polymer or resin containing [i.e., natural or synthetic]
- Y10T428/139—Open-ended, self-supporting conduit, cylinder, or tube-type article
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]
- Y10T428/1352—Polymer or resin containing [i.e., natural or synthetic]
- Y10T428/139—Open-ended, self-supporting conduit, cylinder, or tube-type article
- Y10T428/1393—Multilayer [continuous layer]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T442/00—Fabric [woven, knitted, or nonwoven textile or cloth, etc.]
- Y10T442/60—Nonwoven fabric [i.e., nonwoven strand or fiber material]
- Y10T442/608—Including strand or fiber material which is of specific structural definition
- Y10T442/614—Strand or fiber material specified as having microdimensions [i.e., microfiber]
Abstract
A stent assembly comprising an expensible tubular supporting element and at least one coat of electrospun polymer fibers, each of the at least one coat having a predetermined porosity, the at least one coat including at least one pharmaceutical agent incorporated therein for delivery of the at least one pharmaceutical agent into a body vasculature during or after implantation of the stent assembly within the body vasculature.
Description
MEDICATED POLYMER-COATED STENT ASSEMBLY
FIELD AND BACKGROUND OF THE INVENTION
The present invention relates to an implantable stmt, and, more particularly, to a medicated polymer-coated scent assembly, implantable within a blood vessel designed for delivering a pharmaceutical agent to the surrounding tissues.
Coronary heart disease may result in stenosis, which results in the narrowing or constriction of an artery. Percutaneous coronary intervention (PCI) including balloon angioplasty and scent deployment is currently a mainstay in the treatment of coronary heart disease. This treatment is often associated with acute complications such as late restenosis of angioplastied coronary lesions.
Restenosis refers to the reclosure of a previously stenosed and subsequently dilated peripheral or coronary blood vessel. Restenosis results from an acssesive natural healing process that takes place in response to arterial injuries inherent to angioplasty procedures. This natural healing process involves migration and proliferation of cells. In restenosis this natural healing process continues, sometimes until a complete reclusion of the vessel occurs.
A common solution to restonosis is intercoronary scenting, which is intended to provide the coronary with radial support and thereby prevent constriction. Nevertheless, clinical data indicates that stems are usually unable to prevent late restenosis beginning at about three months following an angioplasty procedure.
To date, attempts have been made to treat restenosis by systemic administration of drugs, and sometimes by intravascular irradiation of the angioplastied artery, however these attempts have not been successful. Hence, current research is being shifted gradually to the local administration of various pharmaceutical agents at the site of an arterial injury resulting from angioplasty.
FIELD AND BACKGROUND OF THE INVENTION
The present invention relates to an implantable stmt, and, more particularly, to a medicated polymer-coated scent assembly, implantable within a blood vessel designed for delivering a pharmaceutical agent to the surrounding tissues.
Coronary heart disease may result in stenosis, which results in the narrowing or constriction of an artery. Percutaneous coronary intervention (PCI) including balloon angioplasty and scent deployment is currently a mainstay in the treatment of coronary heart disease. This treatment is often associated with acute complications such as late restenosis of angioplastied coronary lesions.
Restenosis refers to the reclosure of a previously stenosed and subsequently dilated peripheral or coronary blood vessel. Restenosis results from an acssesive natural healing process that takes place in response to arterial injuries inherent to angioplasty procedures. This natural healing process involves migration and proliferation of cells. In restenosis this natural healing process continues, sometimes until a complete reclusion of the vessel occurs.
A common solution to restonosis is intercoronary scenting, which is intended to provide the coronary with radial support and thereby prevent constriction. Nevertheless, clinical data indicates that stems are usually unable to prevent late restenosis beginning at about three months following an angioplasty procedure.
To date, attempts have been made to treat restenosis by systemic administration of drugs, and sometimes by intravascular irradiation of the angioplastied artery, however these attempts have not been successful. Hence, current research is being shifted gradually to the local administration of various pharmaceutical agents at the site of an arterial injury resulting from angioplasty.
2 The advantages gained by Iocal therapy include higher concentrations of the drug at the actual injury site. One example of such treatment is local drug delivery of toxic drugs such as taxol and rapamycin to the vessel site via a catheter-based delivery system. However, local treatment systems dispensing a medication on a one-shot basis cannot efficiently prevent late restenosis.
Numerous attempts to develop stems with a local drug-distribution function have been made, most of which are variances of the so called stmt graft, a metal stmt covered with polymer envelope, containing anti-coagulant and/or anti-proliferative medicaments. The therapeutic action of stmt grafts is based on gradual decomposition of biodegradable polymers under the effect of aggressive biological medium and drug liberation into the tissues which is in direct contact with the stmt graft location. Drug-loaded polymer can be applied by spraying or by dipping the stmt graft into a solution or melt, as disclosed, for example, in U.S. Patent Nos. 5,383,922, 5,824,048, 5,624,411 and 5,733,327. Additional method for providing a drug-loaded polymer is disclosed in U.S. Patent Nos. 5,637,113 and 5,766,710, where a pre-fabricated film is attached to the stmt. Other methods, such as deposition via photo polymerization, plasma polymerization and the like, are also known in the art and are described in, e.g., U.S. Patent Nos. 3,525,745, 5,609,629 and 5,824,049.
Stent grafts with fiber polymer coating promote preparation of porous coatings with better grafting and highly developed surface. U.S. Patent No.
5,549,663 discloses a stmt graft having a coating made of polyurethane fibers which are applied using conventional wet spinning techniques. Prior to the covering process, a medication is introduced into the polymer.
A more promising method for stmt coating is electrospinning.
Electrospinning is a method for the manufacture of ultra-thin synthetic fibers which reduces the number of technological operations required in the manufacturing process and improves the product being manufactured in more
Numerous attempts to develop stems with a local drug-distribution function have been made, most of which are variances of the so called stmt graft, a metal stmt covered with polymer envelope, containing anti-coagulant and/or anti-proliferative medicaments. The therapeutic action of stmt grafts is based on gradual decomposition of biodegradable polymers under the effect of aggressive biological medium and drug liberation into the tissues which is in direct contact with the stmt graft location. Drug-loaded polymer can be applied by spraying or by dipping the stmt graft into a solution or melt, as disclosed, for example, in U.S. Patent Nos. 5,383,922, 5,824,048, 5,624,411 and 5,733,327. Additional method for providing a drug-loaded polymer is disclosed in U.S. Patent Nos. 5,637,113 and 5,766,710, where a pre-fabricated film is attached to the stmt. Other methods, such as deposition via photo polymerization, plasma polymerization and the like, are also known in the art and are described in, e.g., U.S. Patent Nos. 3,525,745, 5,609,629 and 5,824,049.
Stent grafts with fiber polymer coating promote preparation of porous coatings with better grafting and highly developed surface. U.S. Patent No.
5,549,663 discloses a stmt graft having a coating made of polyurethane fibers which are applied using conventional wet spinning techniques. Prior to the covering process, a medication is introduced into the polymer.
A more promising method for stmt coating is electrospinning.
Electrospinning is a method for the manufacture of ultra-thin synthetic fibers which reduces the number of technological operations required in the manufacturing process and improves the product being manufactured in more
3 than one way. The use of electrospinning for stmt coating permits to obtain durable coating with wide range of fiber thickness (from tens of nanometers to tens of micrometers), achieves exceptional homogeneity, smoothness and desired porosity distribution along the coating thickness. Stems themselves do not encourage normal cellular invasion and therefore can lead to an undisciplined development of cells in the metal mesh of the stmt, giving rise to cellular hyperplasia. When a stmt is electrospinningly coated by a graft of a porous structure, the poxes of the graft component are invaded by cellular tissues from the region of the artery surrounding the stmt graft. Moreover, diversified polymers with various biochemical and physico-mechanical properties can be used in stmt coating. Examples of electrospinning methods in stmt graft manufacturing are found in U.S. Patent Nos. 5,639,278, 5,723,004, 5,948,018, 5,632,772 and 5,855,598.
In is known that the electrospinning technique is rather sensitive to the changes in the electrophysical and rheological parameters of the solution being used in the coating process. In addition, incorporation of drugs into the polymer in a sufficient concentration, so as to achieve a therapeutic effect, reduces the efficiency of the electrospinning process. Still in addition, drug introduction into a polymer reduces the mechanical properties of the resulting coat. Although this drawback is somewhat negligible in relatively thick films, for submicron fibers made film this effect may be adverse.
Beside restenosis, PCI involves the risk of vessel damage during stmt implantation. This risk may be better understood by considering the nature of the defect in the artery, which the stmt is intended to resolve.
Arteriosclerosis or hardening of the arteries is a widespread disease involving practically all arteries of the body including the coronary arteries.
Arteriosclerosis plaques adhere to the walls of the arteries and build up in the course of time to increasingly narrow and constrict the lumens of the arteries.
An appropriate procedure to eradicate this constriction is balloon angioplasty,
In is known that the electrospinning technique is rather sensitive to the changes in the electrophysical and rheological parameters of the solution being used in the coating process. In addition, incorporation of drugs into the polymer in a sufficient concentration, so as to achieve a therapeutic effect, reduces the efficiency of the electrospinning process. Still in addition, drug introduction into a polymer reduces the mechanical properties of the resulting coat. Although this drawback is somewhat negligible in relatively thick films, for submicron fibers made film this effect may be adverse.
Beside restenosis, PCI involves the risk of vessel damage during stmt implantation. This risk may be better understood by considering the nature of the defect in the artery, which the stmt is intended to resolve.
Arteriosclerosis or hardening of the arteries is a widespread disease involving practically all arteries of the body including the coronary arteries.
Arteriosclerosis plaques adhere to the walls of the arteries and build up in the course of time to increasingly narrow and constrict the lumens of the arteries.
An appropriate procedure to eradicate this constriction is balloon angioplasty,
4 andlor stmt placement. In the latter procedure, a stent is transported by a balloon catheter, known as a stmt delivery device, to the defective site in the artery and then expanded radially by the balloon to dilate the site and thereby enlarge the passage through the artery.
As the balloon and/or stmt expands, it then cracks the plaques on the wall of the artery and produces shards or fragments whose sharp edges cut into the tissue. This causes internal bleeding and a possible local infection, which if not adequately treated, may spread and adversely affect other parts of the body.
Local infections in the region of the defective site in an artery do not lend themselves to treatment by injecting an antibiotic into the blood stream of the patient, for such treatment is not usually effective against localized infections. A more common approach to this problem is to coat the wire mesh of the stmt with a therapeutic agent which makes contact with the infected region. As stated, this is a one-shot treatment whereas to knock out infections, it may be necessary to administer an antibiotic and/or other therapeutic agents for several hours or days, or even months.
The risk of vessel damage during stmt implantation may be lowered through the use of a soft stmt serving to improve the biological interface between the stmt and the artery and thereby reduce the risk that the stmt will inflict damage during implantation. Examples of polymeric stems or stmt coatings with biocompatible fibers are found in, for example, U.S. Patent Nos.
6,001,125, 5,376,117 and 5,628,788, all of which are hereby incorporated by reference.
U.S. Patent No. 5,948,018 discloses a graft composed of an expensible stmt component covered by an elastomeric polymeric graft component which, because of its stretchability, does not inhibit expansion of the stmt. The graft component is fabricated by electrospinning to achieve porosity hence to facilitate normal cellular growth. However, U.S. Patent No. 5,948,018 fails to address injuries inflicted by the stmt in the course of its implantation on the
As the balloon and/or stmt expands, it then cracks the plaques on the wall of the artery and produces shards or fragments whose sharp edges cut into the tissue. This causes internal bleeding and a possible local infection, which if not adequately treated, may spread and adversely affect other parts of the body.
Local infections in the region of the defective site in an artery do not lend themselves to treatment by injecting an antibiotic into the blood stream of the patient, for such treatment is not usually effective against localized infections. A more common approach to this problem is to coat the wire mesh of the stmt with a therapeutic agent which makes contact with the infected region. As stated, this is a one-shot treatment whereas to knock out infections, it may be necessary to administer an antibiotic and/or other therapeutic agents for several hours or days, or even months.
The risk of vessel damage during stmt implantation may be lowered through the use of a soft stmt serving to improve the biological interface between the stmt and the artery and thereby reduce the risk that the stmt will inflict damage during implantation. Examples of polymeric stems or stmt coatings with biocompatible fibers are found in, for example, U.S. Patent Nos.
6,001,125, 5,376,117 and 5,628,788, all of which are hereby incorporated by reference.
U.S. Patent No. 5,948,018 discloses a graft composed of an expensible stmt component covered by an elastomeric polymeric graft component which, because of its stretchability, does not inhibit expansion of the stmt. The graft component is fabricated by electrospinning to achieve porosity hence to facilitate normal cellular growth. However, U.S. Patent No. 5,948,018 fails to address injuries inflicted by the stmt in the course of its implantation on the
5 PCT/ILO1/01171 delicate tissues of the artery. These injuries may result in a local infection at the site of the implantation, or lead to other disorders which, unless treated effectively, can cancel out the benefits of the implant.
Additional prior art of interest include: Murphy et al. "Percutaneous 5 Polymeric Stents in Porcine Coronary Arteries", Circulation 86: 1596-1604, 1992; Jeong et al. "Does Heparin Release Coating of the Wallstent limit Thrombosis and Platelet Deposition?", Circulation 92: 173A, 1995; and Wiedermann S.C. "Intercoronary Irradiation Markedly Reduces Necintimal Proliferation after Balloon Angioplasty in Swine" Amer. Col. Cardiol. 25:
1451-1456, 1995.
There is thus a widely recognized need for, and it would be highly advantageous to have, an efficient and reliable medicated polymer-coated stmt assembly, which is implantable within a blood vessel and is designed for delivering a pharmaceutical agent to the surrounding tissues, which is devoid of the above limitations.
According to one aspect of the present invention there is provided a stmt assembly comprising an expensible tubular supporting element and at least one coat of electrospun polymer fibers, each of the at least one coat having a predetermined porosity, the at least one coat including at least one pharmaceutical agent incorporated therein for delivery of the at least one pharmaceutical agent into a body vasculature during or after implantation of the stmt assembly within the body vasculature.
According to another aspect of the present invention there is provided a method of producing a stmt assembly, the method comprising: (a) electrospinning a first liquefied polymer onto an expensible tubular supporting element, thereby coating the tubular supporting element with a first coat having
Additional prior art of interest include: Murphy et al. "Percutaneous 5 Polymeric Stents in Porcine Coronary Arteries", Circulation 86: 1596-1604, 1992; Jeong et al. "Does Heparin Release Coating of the Wallstent limit Thrombosis and Platelet Deposition?", Circulation 92: 173A, 1995; and Wiedermann S.C. "Intercoronary Irradiation Markedly Reduces Necintimal Proliferation after Balloon Angioplasty in Swine" Amer. Col. Cardiol. 25:
1451-1456, 1995.
There is thus a widely recognized need for, and it would be highly advantageous to have, an efficient and reliable medicated polymer-coated stmt assembly, which is implantable within a blood vessel and is designed for delivering a pharmaceutical agent to the surrounding tissues, which is devoid of the above limitations.
According to one aspect of the present invention there is provided a stmt assembly comprising an expensible tubular supporting element and at least one coat of electrospun polymer fibers, each of the at least one coat having a predetermined porosity, the at least one coat including at least one pharmaceutical agent incorporated therein for delivery of the at least one pharmaceutical agent into a body vasculature during or after implantation of the stmt assembly within the body vasculature.
According to another aspect of the present invention there is provided a method of producing a stmt assembly, the method comprising: (a) electrospinning a first liquefied polymer onto an expensible tubular supporting element, thereby coating the tubular supporting element with a first coat having
6 a predetermined porosity; and (b) incorporating at least one pharmaceutical agent into the first coat.
According to yet another aspect of the present invention there is provided a method of treating a constricted blood vessel, the method comprising placing a stmt assembly in the constricted blood vessel, the stmt assembly comprises an expensible tubular supporting element and at least one coat of electrospun polymer fibers, each of the at least one coat having a predetermined porosity, the at least one coat including at least one pharmaceutical agent incorporated therein for delivery of the at least one pharmaceutical agent into a body vasculature during or after implantation of the stmt assembly within the body vasculature.
According to still another aspect of the present invention there is provided a method of dilating a constricted blood vessel, the method comprising: (a) providing a stmt assembly comprises an expensible tubular supporting element and at least one coat of electrospun polymer fibers, each of the at least one coat having a predetermined porosity, the at least one coat including at least one pharmaceutical agent incorporated therein; (b) placing the stmt assembly to a constricted region in the constricted blood vessel; and (c) radially expanding the stmt assembly within the blood vessel so as to dilate the constricted region and to allow blood flow through the blood vessel.
According to an additional aspect of the present invention there is provided a method of coating a medical implant, implantable in a body, the method comprising: (a) electrospinning a first liquef ed polymer onto the medical implant, thereby coating the medical implant with a first coat having a predetermined porosity; and (b) incorporating at least one pharmaceutical agent into the first coat; thereby providing a coated medical implant.
According to further features in preferred embodiments of the invention described below, the at least one pharmaceutical agent is mixed with the liquefied polymer prior to the step of electrospinning, hence the step of incorporating the at least one pharmaceutical agent into the first coat is concomitant with the electrospinning.
According to still further features in the described preferred embodiments the medical implant is selected from the group consisting of a graft, a patch and a valve.
According to still further features in the described preferred embodiments the at least one pharmaceutical agent is dissolved in the in the liquefied polymer.
According to still further features in the described preferred embodiments the at least one pharmaceutical agent is suspended in the liquefied polymer.
According to still further features in the described preferred embodiments the at least one pharmaceutical agent serves for treating at least one disorder in the blood vessel.
According to still further features in the described preferred embodiments the at least one disorder comprises an injury inflicted on tissues of the blood vessel upon implantation of the stmt assembly therein.
According to still further features in the described preferred embodiments the at least one disorder is selected from the group consisting of restenosis and in-stmt stenosis.
According to still further features in the described preferred embodiments the at least one disorder is hyper cell proliferation.
According to still further features in the described preferred embodiments the at least one coat and the at least one pharmaceutical agent are configured and designed so as to provide a predetermined duration of the delivery.
According to still further features in the described preferred embodiments the delivery is by diffusion.
g According to still further features in the described preferred embodiments the delivery is initiated by a radial stretch of the at least one coat, the radial stretch is caused by an expansion of the expensible tubular supporting e1 ement.
According to still further features in the described preferred embodiments the at least one coat comprises an inner coat and an outer coat.
According to still further features in the described preferred embodiments the inner coat comprises a layer lining an inner surface of the expensible tubular supporting element.
According to still further features in the described preferred embodiments the outer coat comprises a layer covering an outer surface of the expensible tubular supporting element.
According to still further features in the described preferred embodiments the at least one pharmaceutical agent is constituted by particles embedded in polymer fibers produced during the step of electrospinning.
According to still further features in the described preferred embodiments the step of incorporating at least one pharmaceutical agent into the first coat comprises constituting the at least one pharmaceutical agent into compact objects, and distributing the compact objects between polymer fibers produced during the step of electrospinning.
According to still further features in the described preferred embodiments the compact objects are capsules.
According to still further features in the described preferred embodiments the compact objects are in a powder form.
According to still further features in the described preferred embodiments the distributing of the compact objects is by spraying.
According to still further features in the described preferred embodiments the expensible tubular supporting element comprises a deformable mesh of stainless steel wires.
According to still further features in the described preferred embodiments the coat is of a tubular structure.
According to still further features in the described preferred embodiments the method further comprising mounting the tubular supporting element onto a rotating mandrel.
According to still further features in the described preferred embodiments the method further comprising electrospinning a second liquefied polymer onto the mandrel, hence providing an inner coat.
According to still further features in the described preferred embodiments the method further comprising electrospinning at least one additional liquefied polymer onto the first coat, hence providing at least one additional coat.
According to still further features in the described preferred embodiments the method further comprising providing at least one adhesion layer onto the tubular supporting element.
According to still further features in the described preferred embodiments the method further comprising providing at least one adhesion layer onto at least one coat.
According to still further features in the described preferred embodiments the adhesion layer is an impervious adhesion layer.
According to still further features in the described preferred embodiments the providing at least one adhesion layer is by electrospinning.
According to still further features in the described preferred embodiments the electrospinning step comprises: (i) charging the liquefied polymer thereby producing a charged liquefied polymer; (ii) subjecting the charged liquefied polymer to a f rst electric field; and (iii) dispensing the charged liquefied polymers within the first electric field in a direction of the mandrel.
According to still further features in the described preferred embodiments the mandrel is of a conductive material.
According to still further features in the described preferred embodiments the first electric field is defined between the mandrel and a 5 dispensing electrode being at a first potential relative to the mandrel.
According to still further features in the described preferred embodiments the method further comprising providing a second electric field defined by a subsidiary electrode being at a second potential relative to the mandrel, the second electric field being for modifying the first electric field.
10 According to still further features in the described preferred embodiments the subsidiary electrode serves for reducing non-uniformities in the first electric field.
According to still further features in the described preferred embodiments the subsidiary electrode serves for controlling fiber orientation of each of the coats.
According to still further features in the described preferred embodiments the mandrel is of a dielectric material.
According to still further features in the described preferred embodiments the tubular supporting element serves as a mandrel.
According to still further features in the described preferred embodiments the first electric field is defined between the tubular supporting element and a dispensing electrode being at a first potential relative to the tubular supporting element.
According to still further features in the described preferred embodiments the method further comprising providing a second electric field defined by a subsidiary electrode being at a second potential relative to the tubular supporting element, the second electric field being for modifying the first electric field.
According to still further features in the described preferred embodiments the first liquefied polymer is a biocompatible liquefied polymer.
According to still further features in the described preferred embodiments the first liquefied polymer is a biodegradable liquefied polymer.
According to still further features in the described preferred embodiments the first liquefied polymer is a biostable liquefied polymer.
According to still further features in the described preferred embodiments first liquefied polymer is a combination of a biodegradable liquefied polymer and a biostable liquefied polymer.
According to still further features in the described preferred embodiments the second liquefied polymer is a biocompatible liquefied polymer.
According to still further features in the described preferred embodiments the second liquefied polymer is a biodegradable liquefied polymer.
According to still further features in the described preferred embodiments the second liquefied polymer is a biostable liquefied polymer.
According to still further features in the described preferred embodiments the second liquefied polymer is a combination of a biodegradable liquefied polymer and a biostable liquefied polymer.
According to still further features in the described preferred embodiments each of the at least one additional liquefied polymer is independently a biocompatible liquefied polymer.
According to still further features in the described preferred embodiments each of the at least one additional liquef ed polymer is independently biodegradable liquefied polymer.
According to still further features in the described preferred embodiments each of the at least one additional liquefied polymer is independently a biostable liquefied polymer.
According to still further features in the described preferred embodiments each of the at least one additional liquefied polymer is independently a combination of a biodegradable liquefied polymer and a biostable liquefied polymer.
According to still further features in the described preferred embodiments the at least one pharmaceutical agent is heparin.
According to still further features in the described preferred embodiments the at least one pharmaceutical agent is a radioactive compound.
According to still further features in the described preferred embodiments the at least one pharmaceutical agent is silver sulfadiazine.
According to still further features in the described preferred embodiments the method further comprising heating the mandrel prior to, during or subsequent to the step of electrospinning.
According to still further features in the described preferred embodiments the heating of the mandrel is selected from the group consisting of external heating and internal heating.
According to still further features in the described preferred embodiments the external heating is by at least one infrared radiator.
According to still further features in the described preferred embodiments the at least one infrared radiator is an infrared lamp.
According to still further features in the described preferred embodiments the internal heating is by a built-in heater.
According to still further features in the described preferred embodiments the built-in heater is an Ohmic built-in heater.
According to still further features in the described preferred embodiments the method further comprising removing the stmt assembly from the mandrel.
According to still further features in the described preferred embodiments the method further comprising dipping the stmt assembly in a vapor.
According to still further features in the described preferred S embodiments the method further comprising heating the vapor.
According to still further features in the described preferred embodiments the vapor is a saturated a DMF vapor.
According to still further features in the described preferred embodiments the method further comprising exposing the stmt assembly to a partial vacuum processing.
The present invention successfully addresses the shortcomings of the presently known configurations by providing a stmt assembly and a method for manufacturing same, the stmt assembly enjoys properties far exceeding those characterizing prior art stmt assemblies.
BRIEF DESCRIPTION OF THE DRAWINGS
The invention is herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of the preferred embodiments of the present invention only, and are presented in the cause of providing what is believed to be the most useful and readily understood description of the principles and conceptual aspects of the invention. In this regard, no attempt is made to show structural details of the invention in more detail than is necessary for a fundamental understanding of the invention, the description taken with the drawings making apparent to those skilled in the art how the several forms of the invention may be embodied in practice.
In the drawings:
FIG. I is a cross-sectional view of a stmt assembly according to the present invention;
FIG. 2a is an end view the stent assembly according to the present invention;
FIG. 2b is an end view of a stmt assembly which further comprises at least one adhesion layer, according to the present invention.
FIG. 3 is a tubular supporting element which is designed and constructed for dilating a constricted blood vessel in a body vasculature;
FIG. 4 is a portion of the tubular supporting element comprising a deformable mesh of metal wires;
FIG. 5 is a stmt assembly, manufactured according to the teachings of the present invention, occupying a defective site in an artery;
FIG. 6 is a portion of a non-woven web of polymer fibers used to fabricate at least one coat, according to the present invention;
FIG. 7 is a portion of a non-woven web of polymer fibers which comprises a pharmaceutical agent constituted by compact objects and distributed between the electrospun polymer fibers;
FIG. 8 is a is a typical, prior art, electrospinning apparatus;
FIG. 9 is an electrospinning apparatus further including a subsidiary electrode according to the present invention;
FIG. I0 is an electrospinning apparatus including an electrostatic sprayer, two baths and two pumps;
FIG. 11 is an electrospinning apparatus including a supply for holding pharmaceutical agent, an electrostatic sprayer and a conical deflector.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
The present invention is of a stmt assembly which can be used for treating a disorder in a blood vessel. Specifically, the present invention can be used to dilate a constricted blood vessel and to deliver pharmaceutical agents) into a body vasculature.
The principles and operation of a stmt assembly according to the present invention may be better understood with reference to the drawings and 5 accompanying descriptions.
Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not limited in its application to the details of construction and the arrangement of the components set forth in the following description or illustrated in the drawings. The invention is capable of 10 other embodiments or of being practiced or carried out in various ways.
Also, it is to be understood that the phraseology and terminology employed'herein is for the purpose of description and should not be regarded as limiting.
Referring now to the drawings, Figure 1 illustrates a cross-sectional view of a stmt assembly according to a preferred embodiment of the present 15 invention. The stmt assembly comprises an expensible tubular supporting element 10 and at least one coat 12, having a predetermined porosity.
According to a presently preferred embodiment of the invention, at least one coat 12 comprises an inner coat 14, lining an inner surface of tubular supporting element 10 and an outer coat 16, covering an outer surface of tubular supporting element 10. Figure 2a illustrates an end view the stmt assembly, showing tubular supporting element I0, internally covered by inner coat 14 and externally covered by outer coat 16. Reference is now made to Figure 2b, illustrating an end view of the stmt assembly in which at least one coat 12 further comprises at least one adhesion layer 15, for adhering the components of the stmt assembly. A method for providing adhesion layer 15 is further detailed hereinafter.
According to a preferred embodiment of the present invention, at least one of the coats includes at least one pharmaceutical agent incorporated therein for delivery of the pharmaceutical agent into a body vasculature during or after implantation of the stmt assembly within the body vasculature. The pharmaceutical agent serves for treating at least one disorder in a blood vessel.
Figure 3 illustrates tubular supporting element 10 which is designed and constructed for dilating a constricted blood vessel in the body vasculature.
Tubular supporting element 10 is operable to expand radially, thereby to dilate a constricted blood vessel. According to a preferred embodiment of the present invention, the expansibility of the stmt assembly may be achieved by a suitable construction of tubular supporting element 10 and of at least one coat 12. The construction of tubular supporting element 10 will be described first, with reference to Figure 4, and the construction of at least one coat 12 will be described thereafter.
Thus, Figure 4 illustrates a portion of tubular supporting element 10 comprising a deformable mesh of metal wires 18, which can be, for example, a deformable mesh of stainless steel wires. Hence, when the stmt assembly is placed in the desired location in an artery, tubular supporting element 10 may be expanded radially, to substantially dilate the arterial tissues surrounding the stmt assembly to eradicate a flow constriction in the artery. The expansion may be performed by any method known in the art, for example by using a balloon catheter or by forming tubular supporting element 10 from a material exhibiting temperature-activated shape memory properties, such as Nitinol.
Tubular supporting element 10 is coated by at least one coat 12 which is fabricated from non-woven polymer fibers using an electrospinning method as is further detailed hereinafter. According to a presently preferred embodiment of the invention, the polymer fibers are elastomeric polymer fibers which stretch as tubular supporting element IO is radially expanded. Referring now again to Figure 1, in a preferred embodiment of the invention at least one coat 12 comprises inner coat 14 and outer coat 16 both of which are coextensive with the tubular supporting element 10, i.e., tubular supporting element 10 is substantially coated. In other embodiments of the invention, inner coat 14 and/or outer coat 16 may be shorter in length than tubular supporting element 10, in which case at least one end of tubular supporting element 10 is exposed.
Still in other embodiments of the invention, inner coat 14 may be absent.
Reference is now made to Figure 5, which illustrate the stmt assembly occupying a defective site 20 in an artery. The outer diameter of the stmt assembly in its unexpanded state, including outer coat 16 coating tubular supporting element 10, is such that it ensures transporting of the stmt assembly through the artery to defective site 20, for example by a catheter. The expensible range of the stmt assembly is such that when in place at defective site 20, the expanded assembly then has a maximum, diameter causing the arterial tissues surrounding the stmt assembly to be dilated to a degree eradicating the flow constriction at the site.
Implantation of the stmt assembly in a blood vessel may result in disorders in the blood vessel, for example an injury inflicted on tissues of the blood vessel upon the implantation, restenosis, in-stmt stenosis and hyper cell proliferation. As stated, at least one coat 12 includes at least one pharmaceutical agent incorporated therein for delivery of the pharmaceutical agent into a body vasculature to treat the above disorders. Hence, at least one coat 12 not only serves to graft the assembly to the artery but also functions as a reservoir for storing the pharmaceutical agent to be delivered over a prolonged time period. Within the above diameter limitation, the larger the aggregate volume of at least one coat 12, the larger its capacity to store the pharmaceutical agent.
In addition, inner coat 14 and outer coat 16 are preferably porous so as to accommodate cells migrating from the surrounding tissues and to facilitate the proliferation of these cells.
Reference is now made to Figure 6 which illustrates a portion of a non-woven web of polymer fibers used to fabricate at least one coat 12. Fibers 22, 24 and 26 intersect and are joined together at the intersections, the resultant l~
interstices rendering the web highly porous. The non-woven web of polymer fibers is produced using an electrospinning process, further described hereinunder, which is capable of producing coatings for forming a graft component having unique advantages. Since electrospun fibers are ultra-thin, they have an exceptionally large surface area, which allows a high quantity of pharmaceutical agent to be incorporated thereon. The surface area of the electrospun polymer fibers approaches that of activated carbon, thereby making the non-woven web of polymer fibers an efficient local drug delivery system.
In addition, the porosity of each of inner coat 14 and outer coat 16 can be controlled independently to create evenly distributed pores of predetermined size and orientation for promoting a high degree of tissue ingrowth and cell endothelization.
The preferred mechanism of pharmaceutical agent release from at least one coat 12 is by diffusion, regardless of the technique employed to embed the pharmaceutical agent therein. The duration of therapeutic drug release in a predetermined concentration depends on several variants, which may be controlled during the manufacturing process. One variant is the chemical nature of the carrier polymer and the chemical means binding the pharmaceutical agent to it. This variant may be controlled by a suitable choice of the polymers) used in the electrospinning process. Another variant is the area of contact between the body and the pharmaceutical agent, which can be controlled by varying the free surface of the electrospun polymer fibers. Also affecting the duration of pharmaceutical agent release is the method used to incorporate the pharmaceutical agent within at least one coat 12, as is further described herein.
According to a preferred embodiment of the present invention, at least one coat 12 includes a number of sub-layers. As a function of their destination, the sub-layers can be differentiated, by fiber orientation, polymer type, pharmaceutical agent incorporated therein, and desired release rate thereof.
Thus, pharmaceutical agent release during the first hours and days following implantation may be achieved by incorporating a solid solution, containing a pharmaceutical agent such as anticoagulants and antithrombogenic agents, in a sub-layer of readily soluble biodegradable polymer fibers. , Thus, during the first period following implantation the pharmaceutical agent that releases includes anticoagulants and antithrombogenic agents.
Referring now again to Figure 6, the pharmaceutical agent may be constituted by particles Z~ embedded in the electrospun polymer fibers forming a sub-layer of at least one coat 12. This method is useful for pharmaceutical agent release during the first post-operative days and weeks. To this end, the pharmaceutical agent can include antimicrobials or antibiotics, thrombolytics, vasodilators, and the like. The duration of the delivery process is effected by the type of polymer used for fabricating the corresponding sub-layer.
Specifically, optimal release rate is ensured by using moderately stable biodegradable polymers.
Reference is now made to Figure 7, which illustrates an alternative method for incorporating the pharmaceutical agent in at least one coat I2, ensuring pharmaceutical agent release during the first post-operative days and weeks. Thus, according to a preferred embodiment of the present invention, the pharmaceutical agent is constituted by compact objects 30 distributed between the electrospun polymer fibers of at least one coat 12. In a presently preferred embodiment of the invention, compact objects 30 may be in any known form, such as, but not limited to, moderately stable biodegradable polymer capsules.
The present invention is also capable of providing release of the pharmaceutical agent, which may last from several months to several years.
According to this embodiment of the present invention, the pharmaceutical agent is dissolved or encapsulated in a sub-layer made of biosatable fibers.
The rate diffusion from within a biostable sub-layer is substantially slower, thereby ensuring a prolonged effect of pharmaceutical agent release. Pharmaceutical agent suitable for such prolonged release include for example, antiplatelets, growth-factor antagonists and free radical scavengers.
Thus, the sequence of pharmaceutical agent release and impact longevity of a certain specific pharmaceutical agents is determined by the type of 5 drug-incorporated polymer, the method in which the pharmaceutical agent is introduced into the electrospun polymer fibers, the sequence of layers forming at least one coat 12, the matrix morphological peculiarities of each layer and by pharmaceutical agent concentration.
These key factors are controlled by the electrospinning method of 10 manufacturing described herein. Although electrospinning can ~be efficiently used for generating large diameter shells, the nature of the electrospinning process prevents efficient generation of products having small diameters, such as a medicated, polymer-coated stmt assembly. In particular, electrospinning manufacturing of small diameter coats result in predominant axial orientation of 15 the fibers leading to a considerable predominance of an axial over radial strength.
While reducing the present invention to practice, it was uncovered that improved mechanical strength of the coating can be achieved when substantially thick and strong fibers are situated.axially, and substantially thin 20 and highly elastic fibers are situated in a transverse (polar) direction.
Thus, according to the present invention there is provided a method of producing a stmt assembly, the method comprising electrospinning a first liquefied polymer onto expensible tubular supporting element 10, thereby coating tubular supporting element 10 with a first coat having a predetermined porosity; and incorporating at least one pharmaceutical agent into the first coat.
As stated, in some embodiments the pharmaceutical agent is mixed with the liquefied polymer prior to the electrospinning process, hence the step of incorporating the pharmaceutical agent into the first coat is concomitant with the step of electrospinning.
The electrospinning steps may be performed using any electrospinning apparatus known in the art. Referring now again to the drawings, Figure 8 illustrate a typical electrospinning apparatus, which includes a pump 40, a mandrel 42 connected to a power supply 43 and a dispensing electrode 44.
Pump 40 is connected to a bath 41 and serves for drawing the liquid polymer stored in bath 41 through a syringe (not shown in Figure 8) into dispensing electrode 44. Mandrel 42 and dispensing electrode 44 are held under a first potential difference, hence generating a first electric field therebetween.
According to the electrospinning method, liquefied polymer is drawn into dispensing electrode 44, and then, subjected to the first electric f eld, charged and dispensed in a direction of mandrel 42. Moving with high velocity in the inter-electrode space, jet of liquefied polymer cools or solvent therein evaporates, thus forming fibers which are collected on the surface of mandrel 42.
Reference is now made to Figure 9, which depicts an electrospinning apparatus used according to another preferred embodiment of the present invention in the manufacturing of the stmt assembly. Hence, the method may further comprise providing a second electric field defined by a subsidiary electrode 46 which is kept at a second potential difference relative to mandrel 42. The purpose of the second electric field (and of the subsidiary electrode 46) is to modify the first electric field, so as to ensure a predetermined fiber orientation while forming the coat. Such predetermined orientation is important, in order to provide a stmt assembly combining the above structural characteristics.
There are two alternatives for providing outer coat 16 of tubular supporting element 10. The first is to mount tubular supporting element 10 on mandrel 42, prior to the electrospinning process, and the second is to use tubular supporting element 10 as a mandrel.
In the preferred embodiment in which mandrel 42 is used as a carrier for tubular supporting element 10, mandrel 42 may function as a metal electrode to which a high voltage is applied to establish the electric field. As a consequence, the polymer fibers emerging from dispensing electrode 44 are projected toward mandrel 42 and form outer coat 16 on tubular supporting element 10. This coating covers both gaps between the metal wires and said metal wires of tubular supporting element 10.
In other embodiments, outer coat 16 exposes the gaps between the metal wires and exclusively covers metal wires of tubular supporting element 10.
This may be achieved either by using tubular supporting element 10 as a mandrel, or by using a dielectric material mandrel, as opposed to a conductive mandrel. Hence, according to this embodiment of the invention the metal mesh of tubular supporting element 10 serves as an electrode to be connected to a source of high voltage to establish an electrostatic field which extends to the stmt but not to the mandrel (in the preferred embodiments in which an isolating mandrel is used). Thus, polymer fibers are exclusively attracted to the wires of tubular supporting element 10 exposing the gaps therebetween. In any case, the resultant polymer-coated stmt therefore has pores which serve for facilitating pharmaceutical agent delivery from the stmt assembly into body vasculature.
According to a preferred embodiment of the present invention the method further comprising providing inner coat 14 which lines the inner surface of tubular supporting element 10. Hence, according to a presently preferred embodiment of the invention, the electrospinning process is first employed so as to directly coat mandrel 42, thereby to provide inner coat 14.
Once mandrel 42 is coated, the electrospinning process is temporarily ceased and tubular supporting element 10 is slipped onto the mandrel and drawn over inner coat 14. Outer coat 16 is then provided by resuming the electrospinning process onto tubular supporting element 10.
Since the operation providing inner coat 14 demands a process cessation for a certain period, a majority of solvent contained in inner coat 14 may be evaporated. This may lead to a poor adhesion between the components of the stmt assembly, once the process is resumed, and might result in the coating stratification following stmt graft opening.
The present invention successfully addresses the above-indicated limitation by two optimized techniques. According to one technique, the outer sub-layer of inner coat 14 and the inner sub-layer of outer coat 16 are each made by electrospinning with upgraded capacity. A typical upgrading can may range from about 50 % to about 100 %. This procedure produce a dense adhesion layer made of thicker fibers with markedly increased solvent content.
A typical thickness of the adhesion layer ranges between about 20 ~m and about 30 ~Cm, which is small compared to the overall diameter of the stmt assembly hence does not produce considerable effect on the coats general parameters. According to an alternative technique, the adhesion layer r comprises an alternative polymer with lower molecular weight than the major polymer, possessing high elastic properties and reactivity.
Other techniques for improving adhesion between the layers and tubular supporting element 10 may also be employed. For example, implementation of various adhesives, primers, welding, chemical binding in the solvent fumes can be used. Examples for suitable materials are silanes such as aminoethyaminopropyl- triacytoxysiIane and the like.
The advantage of using the electrospinning method for fabricating at least one coat 12 is flexibility of choosing the polymer types and fibers thickness, thereby providing a final product having the required combination of strength, elastic and other properties as delineated herein. In addition, an alternating sequence of the sub-layers forming at least one coat 12, each made of differently oriented fibers, determines the porosity distribution nature along the stmt assembly wall thickness. Still in addition, the electrospinning method has the advantage of allowing the incorporation of various chemical components, such as pharmaceutical agents, to be incorporated in the fibers by mixing the pharmaceutical agents in the liquefied polymers prior to electrospinning.
Reference is now made to Figure 10, which depicts an electrospinning apparatus used according to another preferred embodiment of the present invention in the manufacturing of the stmt assembly. In a presently preferred embodiment of the invention, the pharmaceutical agent is mixed with the liquefied polymer in bath 52 prior to the step of electrospinning. Then, the obtained compound is supplied by a pump 50 to an electrostatic sprayer 54 to be sprayed onto tubular supporting element 10 (not shown in Figure 10) which is mounted on mandrel 42. Preferably, axially oriented fibers, which do not essentially contribute to the radial strength properties, can be made of biodegradable polymer and be drug-loaded. Such incorporation of the pharmaceutical agent results in slow release of the agent upon biodegradation of the fibers. The mixing of the pharmaceutical agent in the liquefied polymer may be done using any suitable method, for example by dissolving or suspending. The pharmaceutical agent may be constituted by particles or it may be in a dissolved form.
In the preferred embodiments in which the pharmaceutical agent is to be entrapped in the interstices of the non-woven web at least one coat 12, the agent is preferably in a powder form or micro-encapsulated particulates form so that it can be sprayed as a shower of particles onto a specific layer of at least one coat 12, once formed.
Reference is now made to Figure 11 which depicts electrospinning apparatus used according to a presently preferred embodiment of the present invention. A biocompatible pharmaceutical agent drawn from a supply 58 is fed to electrostatic sprayer 56, whose output is sprayed through a conical deflector 60 to yield a spray of pharmaceutical particles which are directed toward the stmt assembly.
It should be understood, that although the invention has been described in conjunction with tubular supporting element 10, other medical implants, not 5 necessarily of tubular structure, may be coated using the techniques of the present invention. For example, grafts and patches, which may be coated prior to procedure of implantation or application can be drug-loaded and enjoy the advantages as described herein.
The at least one coat 12 may be made from any known biocompatible 10 polymer. In the layers which incorporate pharmaceutical agent, the polymer fibers are preferably a combination of a biodegradable polymer and a biostable polymer.
The list of biostable polymers with a relatively low chronic tissue response include polycarbonate based aliphatic polyurethanes, siloxane based 15 aromatic polyurethanes, polydimethylsiloxane and other silicone rubbers, polyester, polyolefins, polymethyl- methacrylate, vinyl halide polymer and copolymers, polyvinyl aromatics, polyvinyl esters, polyamides, polyimides, polyethers and many others that can be dissolved in appropriate solvents and electrically spun on the stmt.
20 Biodegradable fiber-forming polymers that can be used include poly (L-lactic acid), poly (lactide-co-glycolide), polycaprolactone, polyphosphate ester, poly (hydroxy- butyrate), poly (glycolic acid), poly (DL-lactic acid), poly (amino acid), cyanocrylate, some copolymers and biomolecules such as DNA, silk, chitozan and cellulose.
25 These hydrophilic and hydrophobic polymers which are readily degraded by microorganisms and enzymes are suitable for encapsulating material for drugs. In particular, Polycaprolacton has a slower degradation rate than most other polymers and is therefore especially suitable for controlled-release of pharmaceutical agent over long periods of time scale ranging from about 2 years to about 3 years.
Suitable pharmaceutical agents that can be incorporated in at least ,one coat 12 include heparin, tridodecylmethylammonium-heparin, epothilone A, epothilone B, rotomycine, ticlopidine, dexamethasone, caumadin, and other pharmaceuticals falling generally into the categories of antithrombotic drugs, estrogens, corticosteroids, cytostatics, anticoagulant drugs, vasodilators, and antiplatelet drugs, trombolytics, antimicrobials or antibiotics, antimitotics, antiproliferatives, antisecretory agents, nonsterodial antiflalnmentory drugs, grow factor antagonists, free radical scavengers, antioxidants, radiopaque agents, immunosuppressive agents and radio-labeled agents.
Additional objects, advantages, and novel features of the present invention will become apparent to one ordinarily skilled in the art upon examination of the following examples, which are not intended to be limiting.
Additionally, each of the various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below finds experimental support in the following examples.
EXAMPLES
Reference is now made to the following examples, which together with the above descriptions, illustrate the invention in a non limiting fashion.
Materials, Devices ahd Methods A Carbothane PC-3575A was purchased from Thermedics Polymer Products, and was used for coating. This polymer has satisfactory fiber-generation abilities, it is biocompatibility and is capable of lipophilic drug incorporation. A mixture of dimethylformamide and toluene of ratio ranging from 1:1 to 1:2 was used as a solvent in all experiments.
A PHD 2000 syringe pump was purchased from Harvard Apparatus and was used in the electrospinning apparatus. A spinneret, 0.9 mm in inner diameter, was used as the dispensing electrode. The flow-rate of the spinneret was between 0.05 ml/min and 5 ml/min. The dispensing electrode was grounded while the mandrel was kept at a potential of about 20-50 kV. The mandrel, made of polished stainless steel, was rotated at frequency of 100-150 rotations per minute.
The dispensing electrode was positioned about 25 cm to 35 cm from the precipitation electrode and was connected to the pump with flexible polytetrafluorethylene tubes. Reciprocal motion of the dispensing electrode, - 40 mm in amplitude, was enabled along the mandrel longitudinal axis at a frequency of 2-3 motions/min.
A stmt assembly, 16 mm in length was manufactured using a stainless-steel stmt, 3 mm in diameter in its expanded state, 1.9 mm in diameter in its non-expanded state, as the tubular supporting element. The used stainless-steel stmt is typically intended for catheter and balloon angioplasty.
For adhesion upgrading in polymer coating, the stmt was exposed to 160-180 kJ/m2 corona discharge, rinsed by ethyl alcohol and deionized water, and dried in a nitrogen flow. The concentration of the solution was 8%; the viscosity was 560 cP; and the conductivity 0.8 ~5. For the pharmaceutical agent, heparin in tetrahydrofurane solution was used, at a concentration of 250 U/ml. The polymer to heparin-solution ratio was 100:1. A metal rod, 1.8 mm in diameter and 100 mm in length was used as a mandrel.
To ensure uniform, high-quality coating of an electrode having a low curvature radius, a planar subsidiary electrode was positioned near the mandrel, at a 40 mm distance from the longitudinal axis of the mandrel. The subsidiary electrode potential and the mandrel potential were substantially equal.
A two step coating process was employed. First, the mandrel was coated by electrospinning with polymer fiber layer the thickness of which was about 40 Vim. Once the first step was accomplished, the tubular supporting element was put over the first coat hence an inner coating for the tubular supporting element was obtained. Secondly, an outer coating was applied to the outer surface of the tubular supporting element. The thickness of the outer coat was about 100 Vim.
The stmt assembly was removed from the mandrel, and was placed for about 30 seconds into the saturated DMF vapor atmosphere at 45 °C, so as to ensure upgrading the adhesion strength between the inner coat and the outer coat. Finally, to remove solvent remnants, the stmt was exposed to partial vacuum processing for about 24 hours.
A stent assembly was manufactured as described in Example l, however the pharmaceutical agent was a heparin solution at a concentration of 380 U/ml mixed with 15 % poly (DL-Lactide-CD-Glycolide) solution in chloroform.
In addition, for the dispensing electrode, two simultaneously operating spinnerets were used, mounted one above the other with a height difference of 20 mm therebetween. The first operable to dispense polyurethane while the second operable to dispense the biodegradable polymer poly (L-lactic acid). To ensure desirable correlation between the fiber volumes of polyurethane and the biodegradable polymer, the solution feeding were 0.1 ml/min for the first spinneret and 0.03 ml/min for the second spinneret.
A stmt assembly was manufactured from the materials described in Example 1.
A two step coating process was employed. First, the mandrel was coated by electrospinning with polymer fiber layer the thickness of which was about 60 Vim. Once the first step was accomplished, the tubular supporting element was put over the first coat, hence an inner coating for the tubular supporting element was obtained. Before providing the outer coat, a subsidiary electrode, manufactured as a ring 120 mm in diameter, was mounted 16 mm behind the mandrel.
The subsidiary electrode was made of a wire 1 mm in thickness. The plane engaged by the subsidiary electrode was perpendicular to the mandrel's longitudinal axis. As in Example l, the subsidiary electrode potential and the mandrel potential were substantially equal, however, unlike Example 1, the subsidiary electrode was kinematically connected to the spinneret, so as to allow synchronized motion of the two.
The second coat was applied as in Example l, until an overall thickness of 100 ~.m for the coatings was achieved.
Tests have shown that the fibers of biodegradable heparin-loaded polymer have predominant orientation, coinciding with the mandrel longitudinal axis, whereas the polyurethane fibers have predominant transverse (polar) orientation.
E~iMPLE 4 A stmt assembly was manufactured as described in Example 1, with an aspirin powder added to the polymer solution. The particle root-mean-square (RMS) diameter was 0.2 Vim. The powder mass content in the solution in terms of dry polymer amounted to 3.2 %. For obtaining stable suspension, the composition was mixed for 6 hours using a magnetic stirrer purchased from Freed electric with periodic (1:60) exposure to a 32Khz ultrasound obtained using a PUC40 device.
A stmt assembly was manufactured as described under Example 3, yet the viscosity of the solution employed was higher (770 cP), so was its conductivity (2 ~,S). A solution having these characteristics promotes the 5 production of coarser fibers and a flimsier fabric.
In addition, an aspirin powder was conveyed to a fluidized bed and fed to the spinneret. Sputtering and electrospinning were simultaneous but in an interrupted mode: 5 second sputtering followed by a 60 seconds break. The potential difference between the dispensing electrode and the mandrel was 23 10 kV, the interelectrode separation was 15 cm, and powder feeding rate was mg/min.
A stmt assembly having an outer coat and an inner coat was 15 manufactured as described herein. The outer coat was made of a polymer solution having the parameters specified in Example 4, only a heparin solution was added thereto, as described in Example 3. The scent inner coating was made of polymer solution with the parameters specified in Example l, only a heparin solution was added thereto, as described in Example 3. Thus, the inner 20 coating was characterized by thin fibers and pore size of about 1 Vim. A
coating of this character ensures efficient surface endothelization. The outer surface had pores size of about 5-15 ~,m to ensure the ingrowth of tissues.
25 A stmt assembly was manufactured as described in Example l, except that for both inner coat and outer coat a 6 % ratamycine solution in chloroform was used instead of heparin.
A stmt assembly was manufactured as described in Example l, except that a ticlopidine solution in chloroform was used instead of a heparin solution for the outer coat, whereas the inner coat was manufactured as in Example 1.
A stmt assembly was manufactured from the materials described in Example l, however, before coating by electrospinning the stmt was first dipped into a TECOFLEX Adhesive I-MP solution. In addition, the distance between the mandrel and subsidiary electrode was reduced to 20 mm. Still in addition, the step of post-treatment in solvent vapor was omitted.
The purpose of the present example was to generate an outer coat which exposes the gaps between the metal wires and exclusively covers metal wires of tubular supporting element. Hence, the mandrel was made of a dielectric 1 S material, whereas the tubular supporting element was kept under a potential of 25 kV, via electrical contacts.
Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims.
All publications, patents and patent applications mentioned in this specification are herein incorporated in their entirety by reference into the specification, to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated herein by reference. In addition, citation or identification of any reference in this application shall not be construed as an admthat such reference is available as prior art to the present invention.
According to yet another aspect of the present invention there is provided a method of treating a constricted blood vessel, the method comprising placing a stmt assembly in the constricted blood vessel, the stmt assembly comprises an expensible tubular supporting element and at least one coat of electrospun polymer fibers, each of the at least one coat having a predetermined porosity, the at least one coat including at least one pharmaceutical agent incorporated therein for delivery of the at least one pharmaceutical agent into a body vasculature during or after implantation of the stmt assembly within the body vasculature.
According to still another aspect of the present invention there is provided a method of dilating a constricted blood vessel, the method comprising: (a) providing a stmt assembly comprises an expensible tubular supporting element and at least one coat of electrospun polymer fibers, each of the at least one coat having a predetermined porosity, the at least one coat including at least one pharmaceutical agent incorporated therein; (b) placing the stmt assembly to a constricted region in the constricted blood vessel; and (c) radially expanding the stmt assembly within the blood vessel so as to dilate the constricted region and to allow blood flow through the blood vessel.
According to an additional aspect of the present invention there is provided a method of coating a medical implant, implantable in a body, the method comprising: (a) electrospinning a first liquef ed polymer onto the medical implant, thereby coating the medical implant with a first coat having a predetermined porosity; and (b) incorporating at least one pharmaceutical agent into the first coat; thereby providing a coated medical implant.
According to further features in preferred embodiments of the invention described below, the at least one pharmaceutical agent is mixed with the liquefied polymer prior to the step of electrospinning, hence the step of incorporating the at least one pharmaceutical agent into the first coat is concomitant with the electrospinning.
According to still further features in the described preferred embodiments the medical implant is selected from the group consisting of a graft, a patch and a valve.
According to still further features in the described preferred embodiments the at least one pharmaceutical agent is dissolved in the in the liquefied polymer.
According to still further features in the described preferred embodiments the at least one pharmaceutical agent is suspended in the liquefied polymer.
According to still further features in the described preferred embodiments the at least one pharmaceutical agent serves for treating at least one disorder in the blood vessel.
According to still further features in the described preferred embodiments the at least one disorder comprises an injury inflicted on tissues of the blood vessel upon implantation of the stmt assembly therein.
According to still further features in the described preferred embodiments the at least one disorder is selected from the group consisting of restenosis and in-stmt stenosis.
According to still further features in the described preferred embodiments the at least one disorder is hyper cell proliferation.
According to still further features in the described preferred embodiments the at least one coat and the at least one pharmaceutical agent are configured and designed so as to provide a predetermined duration of the delivery.
According to still further features in the described preferred embodiments the delivery is by diffusion.
g According to still further features in the described preferred embodiments the delivery is initiated by a radial stretch of the at least one coat, the radial stretch is caused by an expansion of the expensible tubular supporting e1 ement.
According to still further features in the described preferred embodiments the at least one coat comprises an inner coat and an outer coat.
According to still further features in the described preferred embodiments the inner coat comprises a layer lining an inner surface of the expensible tubular supporting element.
According to still further features in the described preferred embodiments the outer coat comprises a layer covering an outer surface of the expensible tubular supporting element.
According to still further features in the described preferred embodiments the at least one pharmaceutical agent is constituted by particles embedded in polymer fibers produced during the step of electrospinning.
According to still further features in the described preferred embodiments the step of incorporating at least one pharmaceutical agent into the first coat comprises constituting the at least one pharmaceutical agent into compact objects, and distributing the compact objects between polymer fibers produced during the step of electrospinning.
According to still further features in the described preferred embodiments the compact objects are capsules.
According to still further features in the described preferred embodiments the compact objects are in a powder form.
According to still further features in the described preferred embodiments the distributing of the compact objects is by spraying.
According to still further features in the described preferred embodiments the expensible tubular supporting element comprises a deformable mesh of stainless steel wires.
According to still further features in the described preferred embodiments the coat is of a tubular structure.
According to still further features in the described preferred embodiments the method further comprising mounting the tubular supporting element onto a rotating mandrel.
According to still further features in the described preferred embodiments the method further comprising electrospinning a second liquefied polymer onto the mandrel, hence providing an inner coat.
According to still further features in the described preferred embodiments the method further comprising electrospinning at least one additional liquefied polymer onto the first coat, hence providing at least one additional coat.
According to still further features in the described preferred embodiments the method further comprising providing at least one adhesion layer onto the tubular supporting element.
According to still further features in the described preferred embodiments the method further comprising providing at least one adhesion layer onto at least one coat.
According to still further features in the described preferred embodiments the adhesion layer is an impervious adhesion layer.
According to still further features in the described preferred embodiments the providing at least one adhesion layer is by electrospinning.
According to still further features in the described preferred embodiments the electrospinning step comprises: (i) charging the liquefied polymer thereby producing a charged liquefied polymer; (ii) subjecting the charged liquefied polymer to a f rst electric field; and (iii) dispensing the charged liquefied polymers within the first electric field in a direction of the mandrel.
According to still further features in the described preferred embodiments the mandrel is of a conductive material.
According to still further features in the described preferred embodiments the first electric field is defined between the mandrel and a 5 dispensing electrode being at a first potential relative to the mandrel.
According to still further features in the described preferred embodiments the method further comprising providing a second electric field defined by a subsidiary electrode being at a second potential relative to the mandrel, the second electric field being for modifying the first electric field.
10 According to still further features in the described preferred embodiments the subsidiary electrode serves for reducing non-uniformities in the first electric field.
According to still further features in the described preferred embodiments the subsidiary electrode serves for controlling fiber orientation of each of the coats.
According to still further features in the described preferred embodiments the mandrel is of a dielectric material.
According to still further features in the described preferred embodiments the tubular supporting element serves as a mandrel.
According to still further features in the described preferred embodiments the first electric field is defined between the tubular supporting element and a dispensing electrode being at a first potential relative to the tubular supporting element.
According to still further features in the described preferred embodiments the method further comprising providing a second electric field defined by a subsidiary electrode being at a second potential relative to the tubular supporting element, the second electric field being for modifying the first electric field.
According to still further features in the described preferred embodiments the first liquefied polymer is a biocompatible liquefied polymer.
According to still further features in the described preferred embodiments the first liquefied polymer is a biodegradable liquefied polymer.
According to still further features in the described preferred embodiments the first liquefied polymer is a biostable liquefied polymer.
According to still further features in the described preferred embodiments first liquefied polymer is a combination of a biodegradable liquefied polymer and a biostable liquefied polymer.
According to still further features in the described preferred embodiments the second liquefied polymer is a biocompatible liquefied polymer.
According to still further features in the described preferred embodiments the second liquefied polymer is a biodegradable liquefied polymer.
According to still further features in the described preferred embodiments the second liquefied polymer is a biostable liquefied polymer.
According to still further features in the described preferred embodiments the second liquefied polymer is a combination of a biodegradable liquefied polymer and a biostable liquefied polymer.
According to still further features in the described preferred embodiments each of the at least one additional liquefied polymer is independently a biocompatible liquefied polymer.
According to still further features in the described preferred embodiments each of the at least one additional liquef ed polymer is independently biodegradable liquefied polymer.
According to still further features in the described preferred embodiments each of the at least one additional liquefied polymer is independently a biostable liquefied polymer.
According to still further features in the described preferred embodiments each of the at least one additional liquefied polymer is independently a combination of a biodegradable liquefied polymer and a biostable liquefied polymer.
According to still further features in the described preferred embodiments the at least one pharmaceutical agent is heparin.
According to still further features in the described preferred embodiments the at least one pharmaceutical agent is a radioactive compound.
According to still further features in the described preferred embodiments the at least one pharmaceutical agent is silver sulfadiazine.
According to still further features in the described preferred embodiments the method further comprising heating the mandrel prior to, during or subsequent to the step of electrospinning.
According to still further features in the described preferred embodiments the heating of the mandrel is selected from the group consisting of external heating and internal heating.
According to still further features in the described preferred embodiments the external heating is by at least one infrared radiator.
According to still further features in the described preferred embodiments the at least one infrared radiator is an infrared lamp.
According to still further features in the described preferred embodiments the internal heating is by a built-in heater.
According to still further features in the described preferred embodiments the built-in heater is an Ohmic built-in heater.
According to still further features in the described preferred embodiments the method further comprising removing the stmt assembly from the mandrel.
According to still further features in the described preferred embodiments the method further comprising dipping the stmt assembly in a vapor.
According to still further features in the described preferred S embodiments the method further comprising heating the vapor.
According to still further features in the described preferred embodiments the vapor is a saturated a DMF vapor.
According to still further features in the described preferred embodiments the method further comprising exposing the stmt assembly to a partial vacuum processing.
The present invention successfully addresses the shortcomings of the presently known configurations by providing a stmt assembly and a method for manufacturing same, the stmt assembly enjoys properties far exceeding those characterizing prior art stmt assemblies.
BRIEF DESCRIPTION OF THE DRAWINGS
The invention is herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of the preferred embodiments of the present invention only, and are presented in the cause of providing what is believed to be the most useful and readily understood description of the principles and conceptual aspects of the invention. In this regard, no attempt is made to show structural details of the invention in more detail than is necessary for a fundamental understanding of the invention, the description taken with the drawings making apparent to those skilled in the art how the several forms of the invention may be embodied in practice.
In the drawings:
FIG. I is a cross-sectional view of a stmt assembly according to the present invention;
FIG. 2a is an end view the stent assembly according to the present invention;
FIG. 2b is an end view of a stmt assembly which further comprises at least one adhesion layer, according to the present invention.
FIG. 3 is a tubular supporting element which is designed and constructed for dilating a constricted blood vessel in a body vasculature;
FIG. 4 is a portion of the tubular supporting element comprising a deformable mesh of metal wires;
FIG. 5 is a stmt assembly, manufactured according to the teachings of the present invention, occupying a defective site in an artery;
FIG. 6 is a portion of a non-woven web of polymer fibers used to fabricate at least one coat, according to the present invention;
FIG. 7 is a portion of a non-woven web of polymer fibers which comprises a pharmaceutical agent constituted by compact objects and distributed between the electrospun polymer fibers;
FIG. 8 is a is a typical, prior art, electrospinning apparatus;
FIG. 9 is an electrospinning apparatus further including a subsidiary electrode according to the present invention;
FIG. I0 is an electrospinning apparatus including an electrostatic sprayer, two baths and two pumps;
FIG. 11 is an electrospinning apparatus including a supply for holding pharmaceutical agent, an electrostatic sprayer and a conical deflector.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
The present invention is of a stmt assembly which can be used for treating a disorder in a blood vessel. Specifically, the present invention can be used to dilate a constricted blood vessel and to deliver pharmaceutical agents) into a body vasculature.
The principles and operation of a stmt assembly according to the present invention may be better understood with reference to the drawings and 5 accompanying descriptions.
Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not limited in its application to the details of construction and the arrangement of the components set forth in the following description or illustrated in the drawings. The invention is capable of 10 other embodiments or of being practiced or carried out in various ways.
Also, it is to be understood that the phraseology and terminology employed'herein is for the purpose of description and should not be regarded as limiting.
Referring now to the drawings, Figure 1 illustrates a cross-sectional view of a stmt assembly according to a preferred embodiment of the present 15 invention. The stmt assembly comprises an expensible tubular supporting element 10 and at least one coat 12, having a predetermined porosity.
According to a presently preferred embodiment of the invention, at least one coat 12 comprises an inner coat 14, lining an inner surface of tubular supporting element 10 and an outer coat 16, covering an outer surface of tubular supporting element 10. Figure 2a illustrates an end view the stmt assembly, showing tubular supporting element I0, internally covered by inner coat 14 and externally covered by outer coat 16. Reference is now made to Figure 2b, illustrating an end view of the stmt assembly in which at least one coat 12 further comprises at least one adhesion layer 15, for adhering the components of the stmt assembly. A method for providing adhesion layer 15 is further detailed hereinafter.
According to a preferred embodiment of the present invention, at least one of the coats includes at least one pharmaceutical agent incorporated therein for delivery of the pharmaceutical agent into a body vasculature during or after implantation of the stmt assembly within the body vasculature. The pharmaceutical agent serves for treating at least one disorder in a blood vessel.
Figure 3 illustrates tubular supporting element 10 which is designed and constructed for dilating a constricted blood vessel in the body vasculature.
Tubular supporting element 10 is operable to expand radially, thereby to dilate a constricted blood vessel. According to a preferred embodiment of the present invention, the expansibility of the stmt assembly may be achieved by a suitable construction of tubular supporting element 10 and of at least one coat 12. The construction of tubular supporting element 10 will be described first, with reference to Figure 4, and the construction of at least one coat 12 will be described thereafter.
Thus, Figure 4 illustrates a portion of tubular supporting element 10 comprising a deformable mesh of metal wires 18, which can be, for example, a deformable mesh of stainless steel wires. Hence, when the stmt assembly is placed in the desired location in an artery, tubular supporting element 10 may be expanded radially, to substantially dilate the arterial tissues surrounding the stmt assembly to eradicate a flow constriction in the artery. The expansion may be performed by any method known in the art, for example by using a balloon catheter or by forming tubular supporting element 10 from a material exhibiting temperature-activated shape memory properties, such as Nitinol.
Tubular supporting element 10 is coated by at least one coat 12 which is fabricated from non-woven polymer fibers using an electrospinning method as is further detailed hereinafter. According to a presently preferred embodiment of the invention, the polymer fibers are elastomeric polymer fibers which stretch as tubular supporting element IO is radially expanded. Referring now again to Figure 1, in a preferred embodiment of the invention at least one coat 12 comprises inner coat 14 and outer coat 16 both of which are coextensive with the tubular supporting element 10, i.e., tubular supporting element 10 is substantially coated. In other embodiments of the invention, inner coat 14 and/or outer coat 16 may be shorter in length than tubular supporting element 10, in which case at least one end of tubular supporting element 10 is exposed.
Still in other embodiments of the invention, inner coat 14 may be absent.
Reference is now made to Figure 5, which illustrate the stmt assembly occupying a defective site 20 in an artery. The outer diameter of the stmt assembly in its unexpanded state, including outer coat 16 coating tubular supporting element 10, is such that it ensures transporting of the stmt assembly through the artery to defective site 20, for example by a catheter. The expensible range of the stmt assembly is such that when in place at defective site 20, the expanded assembly then has a maximum, diameter causing the arterial tissues surrounding the stmt assembly to be dilated to a degree eradicating the flow constriction at the site.
Implantation of the stmt assembly in a blood vessel may result in disorders in the blood vessel, for example an injury inflicted on tissues of the blood vessel upon the implantation, restenosis, in-stmt stenosis and hyper cell proliferation. As stated, at least one coat 12 includes at least one pharmaceutical agent incorporated therein for delivery of the pharmaceutical agent into a body vasculature to treat the above disorders. Hence, at least one coat 12 not only serves to graft the assembly to the artery but also functions as a reservoir for storing the pharmaceutical agent to be delivered over a prolonged time period. Within the above diameter limitation, the larger the aggregate volume of at least one coat 12, the larger its capacity to store the pharmaceutical agent.
In addition, inner coat 14 and outer coat 16 are preferably porous so as to accommodate cells migrating from the surrounding tissues and to facilitate the proliferation of these cells.
Reference is now made to Figure 6 which illustrates a portion of a non-woven web of polymer fibers used to fabricate at least one coat 12. Fibers 22, 24 and 26 intersect and are joined together at the intersections, the resultant l~
interstices rendering the web highly porous. The non-woven web of polymer fibers is produced using an electrospinning process, further described hereinunder, which is capable of producing coatings for forming a graft component having unique advantages. Since electrospun fibers are ultra-thin, they have an exceptionally large surface area, which allows a high quantity of pharmaceutical agent to be incorporated thereon. The surface area of the electrospun polymer fibers approaches that of activated carbon, thereby making the non-woven web of polymer fibers an efficient local drug delivery system.
In addition, the porosity of each of inner coat 14 and outer coat 16 can be controlled independently to create evenly distributed pores of predetermined size and orientation for promoting a high degree of tissue ingrowth and cell endothelization.
The preferred mechanism of pharmaceutical agent release from at least one coat 12 is by diffusion, regardless of the technique employed to embed the pharmaceutical agent therein. The duration of therapeutic drug release in a predetermined concentration depends on several variants, which may be controlled during the manufacturing process. One variant is the chemical nature of the carrier polymer and the chemical means binding the pharmaceutical agent to it. This variant may be controlled by a suitable choice of the polymers) used in the electrospinning process. Another variant is the area of contact between the body and the pharmaceutical agent, which can be controlled by varying the free surface of the electrospun polymer fibers. Also affecting the duration of pharmaceutical agent release is the method used to incorporate the pharmaceutical agent within at least one coat 12, as is further described herein.
According to a preferred embodiment of the present invention, at least one coat 12 includes a number of sub-layers. As a function of their destination, the sub-layers can be differentiated, by fiber orientation, polymer type, pharmaceutical agent incorporated therein, and desired release rate thereof.
Thus, pharmaceutical agent release during the first hours and days following implantation may be achieved by incorporating a solid solution, containing a pharmaceutical agent such as anticoagulants and antithrombogenic agents, in a sub-layer of readily soluble biodegradable polymer fibers. , Thus, during the first period following implantation the pharmaceutical agent that releases includes anticoagulants and antithrombogenic agents.
Referring now again to Figure 6, the pharmaceutical agent may be constituted by particles Z~ embedded in the electrospun polymer fibers forming a sub-layer of at least one coat 12. This method is useful for pharmaceutical agent release during the first post-operative days and weeks. To this end, the pharmaceutical agent can include antimicrobials or antibiotics, thrombolytics, vasodilators, and the like. The duration of the delivery process is effected by the type of polymer used for fabricating the corresponding sub-layer.
Specifically, optimal release rate is ensured by using moderately stable biodegradable polymers.
Reference is now made to Figure 7, which illustrates an alternative method for incorporating the pharmaceutical agent in at least one coat I2, ensuring pharmaceutical agent release during the first post-operative days and weeks. Thus, according to a preferred embodiment of the present invention, the pharmaceutical agent is constituted by compact objects 30 distributed between the electrospun polymer fibers of at least one coat 12. In a presently preferred embodiment of the invention, compact objects 30 may be in any known form, such as, but not limited to, moderately stable biodegradable polymer capsules.
The present invention is also capable of providing release of the pharmaceutical agent, which may last from several months to several years.
According to this embodiment of the present invention, the pharmaceutical agent is dissolved or encapsulated in a sub-layer made of biosatable fibers.
The rate diffusion from within a biostable sub-layer is substantially slower, thereby ensuring a prolonged effect of pharmaceutical agent release. Pharmaceutical agent suitable for such prolonged release include for example, antiplatelets, growth-factor antagonists and free radical scavengers.
Thus, the sequence of pharmaceutical agent release and impact longevity of a certain specific pharmaceutical agents is determined by the type of 5 drug-incorporated polymer, the method in which the pharmaceutical agent is introduced into the electrospun polymer fibers, the sequence of layers forming at least one coat 12, the matrix morphological peculiarities of each layer and by pharmaceutical agent concentration.
These key factors are controlled by the electrospinning method of 10 manufacturing described herein. Although electrospinning can ~be efficiently used for generating large diameter shells, the nature of the electrospinning process prevents efficient generation of products having small diameters, such as a medicated, polymer-coated stmt assembly. In particular, electrospinning manufacturing of small diameter coats result in predominant axial orientation of 15 the fibers leading to a considerable predominance of an axial over radial strength.
While reducing the present invention to practice, it was uncovered that improved mechanical strength of the coating can be achieved when substantially thick and strong fibers are situated.axially, and substantially thin 20 and highly elastic fibers are situated in a transverse (polar) direction.
Thus, according to the present invention there is provided a method of producing a stmt assembly, the method comprising electrospinning a first liquefied polymer onto expensible tubular supporting element 10, thereby coating tubular supporting element 10 with a first coat having a predetermined porosity; and incorporating at least one pharmaceutical agent into the first coat.
As stated, in some embodiments the pharmaceutical agent is mixed with the liquefied polymer prior to the electrospinning process, hence the step of incorporating the pharmaceutical agent into the first coat is concomitant with the step of electrospinning.
The electrospinning steps may be performed using any electrospinning apparatus known in the art. Referring now again to the drawings, Figure 8 illustrate a typical electrospinning apparatus, which includes a pump 40, a mandrel 42 connected to a power supply 43 and a dispensing electrode 44.
Pump 40 is connected to a bath 41 and serves for drawing the liquid polymer stored in bath 41 through a syringe (not shown in Figure 8) into dispensing electrode 44. Mandrel 42 and dispensing electrode 44 are held under a first potential difference, hence generating a first electric field therebetween.
According to the electrospinning method, liquefied polymer is drawn into dispensing electrode 44, and then, subjected to the first electric f eld, charged and dispensed in a direction of mandrel 42. Moving with high velocity in the inter-electrode space, jet of liquefied polymer cools or solvent therein evaporates, thus forming fibers which are collected on the surface of mandrel 42.
Reference is now made to Figure 9, which depicts an electrospinning apparatus used according to another preferred embodiment of the present invention in the manufacturing of the stmt assembly. Hence, the method may further comprise providing a second electric field defined by a subsidiary electrode 46 which is kept at a second potential difference relative to mandrel 42. The purpose of the second electric field (and of the subsidiary electrode 46) is to modify the first electric field, so as to ensure a predetermined fiber orientation while forming the coat. Such predetermined orientation is important, in order to provide a stmt assembly combining the above structural characteristics.
There are two alternatives for providing outer coat 16 of tubular supporting element 10. The first is to mount tubular supporting element 10 on mandrel 42, prior to the electrospinning process, and the second is to use tubular supporting element 10 as a mandrel.
In the preferred embodiment in which mandrel 42 is used as a carrier for tubular supporting element 10, mandrel 42 may function as a metal electrode to which a high voltage is applied to establish the electric field. As a consequence, the polymer fibers emerging from dispensing electrode 44 are projected toward mandrel 42 and form outer coat 16 on tubular supporting element 10. This coating covers both gaps between the metal wires and said metal wires of tubular supporting element 10.
In other embodiments, outer coat 16 exposes the gaps between the metal wires and exclusively covers metal wires of tubular supporting element 10.
This may be achieved either by using tubular supporting element 10 as a mandrel, or by using a dielectric material mandrel, as opposed to a conductive mandrel. Hence, according to this embodiment of the invention the metal mesh of tubular supporting element 10 serves as an electrode to be connected to a source of high voltage to establish an electrostatic field which extends to the stmt but not to the mandrel (in the preferred embodiments in which an isolating mandrel is used). Thus, polymer fibers are exclusively attracted to the wires of tubular supporting element 10 exposing the gaps therebetween. In any case, the resultant polymer-coated stmt therefore has pores which serve for facilitating pharmaceutical agent delivery from the stmt assembly into body vasculature.
According to a preferred embodiment of the present invention the method further comprising providing inner coat 14 which lines the inner surface of tubular supporting element 10. Hence, according to a presently preferred embodiment of the invention, the electrospinning process is first employed so as to directly coat mandrel 42, thereby to provide inner coat 14.
Once mandrel 42 is coated, the electrospinning process is temporarily ceased and tubular supporting element 10 is slipped onto the mandrel and drawn over inner coat 14. Outer coat 16 is then provided by resuming the electrospinning process onto tubular supporting element 10.
Since the operation providing inner coat 14 demands a process cessation for a certain period, a majority of solvent contained in inner coat 14 may be evaporated. This may lead to a poor adhesion between the components of the stmt assembly, once the process is resumed, and might result in the coating stratification following stmt graft opening.
The present invention successfully addresses the above-indicated limitation by two optimized techniques. According to one technique, the outer sub-layer of inner coat 14 and the inner sub-layer of outer coat 16 are each made by electrospinning with upgraded capacity. A typical upgrading can may range from about 50 % to about 100 %. This procedure produce a dense adhesion layer made of thicker fibers with markedly increased solvent content.
A typical thickness of the adhesion layer ranges between about 20 ~m and about 30 ~Cm, which is small compared to the overall diameter of the stmt assembly hence does not produce considerable effect on the coats general parameters. According to an alternative technique, the adhesion layer r comprises an alternative polymer with lower molecular weight than the major polymer, possessing high elastic properties and reactivity.
Other techniques for improving adhesion between the layers and tubular supporting element 10 may also be employed. For example, implementation of various adhesives, primers, welding, chemical binding in the solvent fumes can be used. Examples for suitable materials are silanes such as aminoethyaminopropyl- triacytoxysiIane and the like.
The advantage of using the electrospinning method for fabricating at least one coat 12 is flexibility of choosing the polymer types and fibers thickness, thereby providing a final product having the required combination of strength, elastic and other properties as delineated herein. In addition, an alternating sequence of the sub-layers forming at least one coat 12, each made of differently oriented fibers, determines the porosity distribution nature along the stmt assembly wall thickness. Still in addition, the electrospinning method has the advantage of allowing the incorporation of various chemical components, such as pharmaceutical agents, to be incorporated in the fibers by mixing the pharmaceutical agents in the liquefied polymers prior to electrospinning.
Reference is now made to Figure 10, which depicts an electrospinning apparatus used according to another preferred embodiment of the present invention in the manufacturing of the stmt assembly. In a presently preferred embodiment of the invention, the pharmaceutical agent is mixed with the liquefied polymer in bath 52 prior to the step of electrospinning. Then, the obtained compound is supplied by a pump 50 to an electrostatic sprayer 54 to be sprayed onto tubular supporting element 10 (not shown in Figure 10) which is mounted on mandrel 42. Preferably, axially oriented fibers, which do not essentially contribute to the radial strength properties, can be made of biodegradable polymer and be drug-loaded. Such incorporation of the pharmaceutical agent results in slow release of the agent upon biodegradation of the fibers. The mixing of the pharmaceutical agent in the liquefied polymer may be done using any suitable method, for example by dissolving or suspending. The pharmaceutical agent may be constituted by particles or it may be in a dissolved form.
In the preferred embodiments in which the pharmaceutical agent is to be entrapped in the interstices of the non-woven web at least one coat 12, the agent is preferably in a powder form or micro-encapsulated particulates form so that it can be sprayed as a shower of particles onto a specific layer of at least one coat 12, once formed.
Reference is now made to Figure 11 which depicts electrospinning apparatus used according to a presently preferred embodiment of the present invention. A biocompatible pharmaceutical agent drawn from a supply 58 is fed to electrostatic sprayer 56, whose output is sprayed through a conical deflector 60 to yield a spray of pharmaceutical particles which are directed toward the stmt assembly.
It should be understood, that although the invention has been described in conjunction with tubular supporting element 10, other medical implants, not 5 necessarily of tubular structure, may be coated using the techniques of the present invention. For example, grafts and patches, which may be coated prior to procedure of implantation or application can be drug-loaded and enjoy the advantages as described herein.
The at least one coat 12 may be made from any known biocompatible 10 polymer. In the layers which incorporate pharmaceutical agent, the polymer fibers are preferably a combination of a biodegradable polymer and a biostable polymer.
The list of biostable polymers with a relatively low chronic tissue response include polycarbonate based aliphatic polyurethanes, siloxane based 15 aromatic polyurethanes, polydimethylsiloxane and other silicone rubbers, polyester, polyolefins, polymethyl- methacrylate, vinyl halide polymer and copolymers, polyvinyl aromatics, polyvinyl esters, polyamides, polyimides, polyethers and many others that can be dissolved in appropriate solvents and electrically spun on the stmt.
20 Biodegradable fiber-forming polymers that can be used include poly (L-lactic acid), poly (lactide-co-glycolide), polycaprolactone, polyphosphate ester, poly (hydroxy- butyrate), poly (glycolic acid), poly (DL-lactic acid), poly (amino acid), cyanocrylate, some copolymers and biomolecules such as DNA, silk, chitozan and cellulose.
25 These hydrophilic and hydrophobic polymers which are readily degraded by microorganisms and enzymes are suitable for encapsulating material for drugs. In particular, Polycaprolacton has a slower degradation rate than most other polymers and is therefore especially suitable for controlled-release of pharmaceutical agent over long periods of time scale ranging from about 2 years to about 3 years.
Suitable pharmaceutical agents that can be incorporated in at least ,one coat 12 include heparin, tridodecylmethylammonium-heparin, epothilone A, epothilone B, rotomycine, ticlopidine, dexamethasone, caumadin, and other pharmaceuticals falling generally into the categories of antithrombotic drugs, estrogens, corticosteroids, cytostatics, anticoagulant drugs, vasodilators, and antiplatelet drugs, trombolytics, antimicrobials or antibiotics, antimitotics, antiproliferatives, antisecretory agents, nonsterodial antiflalnmentory drugs, grow factor antagonists, free radical scavengers, antioxidants, radiopaque agents, immunosuppressive agents and radio-labeled agents.
Additional objects, advantages, and novel features of the present invention will become apparent to one ordinarily skilled in the art upon examination of the following examples, which are not intended to be limiting.
Additionally, each of the various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below finds experimental support in the following examples.
EXAMPLES
Reference is now made to the following examples, which together with the above descriptions, illustrate the invention in a non limiting fashion.
Materials, Devices ahd Methods A Carbothane PC-3575A was purchased from Thermedics Polymer Products, and was used for coating. This polymer has satisfactory fiber-generation abilities, it is biocompatibility and is capable of lipophilic drug incorporation. A mixture of dimethylformamide and toluene of ratio ranging from 1:1 to 1:2 was used as a solvent in all experiments.
A PHD 2000 syringe pump was purchased from Harvard Apparatus and was used in the electrospinning apparatus. A spinneret, 0.9 mm in inner diameter, was used as the dispensing electrode. The flow-rate of the spinneret was between 0.05 ml/min and 5 ml/min. The dispensing electrode was grounded while the mandrel was kept at a potential of about 20-50 kV. The mandrel, made of polished stainless steel, was rotated at frequency of 100-150 rotations per minute.
The dispensing electrode was positioned about 25 cm to 35 cm from the precipitation electrode and was connected to the pump with flexible polytetrafluorethylene tubes. Reciprocal motion of the dispensing electrode, - 40 mm in amplitude, was enabled along the mandrel longitudinal axis at a frequency of 2-3 motions/min.
A stmt assembly, 16 mm in length was manufactured using a stainless-steel stmt, 3 mm in diameter in its expanded state, 1.9 mm in diameter in its non-expanded state, as the tubular supporting element. The used stainless-steel stmt is typically intended for catheter and balloon angioplasty.
For adhesion upgrading in polymer coating, the stmt was exposed to 160-180 kJ/m2 corona discharge, rinsed by ethyl alcohol and deionized water, and dried in a nitrogen flow. The concentration of the solution was 8%; the viscosity was 560 cP; and the conductivity 0.8 ~5. For the pharmaceutical agent, heparin in tetrahydrofurane solution was used, at a concentration of 250 U/ml. The polymer to heparin-solution ratio was 100:1. A metal rod, 1.8 mm in diameter and 100 mm in length was used as a mandrel.
To ensure uniform, high-quality coating of an electrode having a low curvature radius, a planar subsidiary electrode was positioned near the mandrel, at a 40 mm distance from the longitudinal axis of the mandrel. The subsidiary electrode potential and the mandrel potential were substantially equal.
A two step coating process was employed. First, the mandrel was coated by electrospinning with polymer fiber layer the thickness of which was about 40 Vim. Once the first step was accomplished, the tubular supporting element was put over the first coat hence an inner coating for the tubular supporting element was obtained. Secondly, an outer coating was applied to the outer surface of the tubular supporting element. The thickness of the outer coat was about 100 Vim.
The stmt assembly was removed from the mandrel, and was placed for about 30 seconds into the saturated DMF vapor atmosphere at 45 °C, so as to ensure upgrading the adhesion strength between the inner coat and the outer coat. Finally, to remove solvent remnants, the stmt was exposed to partial vacuum processing for about 24 hours.
A stent assembly was manufactured as described in Example l, however the pharmaceutical agent was a heparin solution at a concentration of 380 U/ml mixed with 15 % poly (DL-Lactide-CD-Glycolide) solution in chloroform.
In addition, for the dispensing electrode, two simultaneously operating spinnerets were used, mounted one above the other with a height difference of 20 mm therebetween. The first operable to dispense polyurethane while the second operable to dispense the biodegradable polymer poly (L-lactic acid). To ensure desirable correlation between the fiber volumes of polyurethane and the biodegradable polymer, the solution feeding were 0.1 ml/min for the first spinneret and 0.03 ml/min for the second spinneret.
A stmt assembly was manufactured from the materials described in Example 1.
A two step coating process was employed. First, the mandrel was coated by electrospinning with polymer fiber layer the thickness of which was about 60 Vim. Once the first step was accomplished, the tubular supporting element was put over the first coat, hence an inner coating for the tubular supporting element was obtained. Before providing the outer coat, a subsidiary electrode, manufactured as a ring 120 mm in diameter, was mounted 16 mm behind the mandrel.
The subsidiary electrode was made of a wire 1 mm in thickness. The plane engaged by the subsidiary electrode was perpendicular to the mandrel's longitudinal axis. As in Example l, the subsidiary electrode potential and the mandrel potential were substantially equal, however, unlike Example 1, the subsidiary electrode was kinematically connected to the spinneret, so as to allow synchronized motion of the two.
The second coat was applied as in Example l, until an overall thickness of 100 ~.m for the coatings was achieved.
Tests have shown that the fibers of biodegradable heparin-loaded polymer have predominant orientation, coinciding with the mandrel longitudinal axis, whereas the polyurethane fibers have predominant transverse (polar) orientation.
E~iMPLE 4 A stmt assembly was manufactured as described in Example 1, with an aspirin powder added to the polymer solution. The particle root-mean-square (RMS) diameter was 0.2 Vim. The powder mass content in the solution in terms of dry polymer amounted to 3.2 %. For obtaining stable suspension, the composition was mixed for 6 hours using a magnetic stirrer purchased from Freed electric with periodic (1:60) exposure to a 32Khz ultrasound obtained using a PUC40 device.
A stmt assembly was manufactured as described under Example 3, yet the viscosity of the solution employed was higher (770 cP), so was its conductivity (2 ~,S). A solution having these characteristics promotes the 5 production of coarser fibers and a flimsier fabric.
In addition, an aspirin powder was conveyed to a fluidized bed and fed to the spinneret. Sputtering and electrospinning were simultaneous but in an interrupted mode: 5 second sputtering followed by a 60 seconds break. The potential difference between the dispensing electrode and the mandrel was 23 10 kV, the interelectrode separation was 15 cm, and powder feeding rate was mg/min.
A stmt assembly having an outer coat and an inner coat was 15 manufactured as described herein. The outer coat was made of a polymer solution having the parameters specified in Example 4, only a heparin solution was added thereto, as described in Example 3. The scent inner coating was made of polymer solution with the parameters specified in Example l, only a heparin solution was added thereto, as described in Example 3. Thus, the inner 20 coating was characterized by thin fibers and pore size of about 1 Vim. A
coating of this character ensures efficient surface endothelization. The outer surface had pores size of about 5-15 ~,m to ensure the ingrowth of tissues.
25 A stmt assembly was manufactured as described in Example l, except that for both inner coat and outer coat a 6 % ratamycine solution in chloroform was used instead of heparin.
A stmt assembly was manufactured as described in Example l, except that a ticlopidine solution in chloroform was used instead of a heparin solution for the outer coat, whereas the inner coat was manufactured as in Example 1.
A stmt assembly was manufactured from the materials described in Example l, however, before coating by electrospinning the stmt was first dipped into a TECOFLEX Adhesive I-MP solution. In addition, the distance between the mandrel and subsidiary electrode was reduced to 20 mm. Still in addition, the step of post-treatment in solvent vapor was omitted.
The purpose of the present example was to generate an outer coat which exposes the gaps between the metal wires and exclusively covers metal wires of tubular supporting element. Hence, the mandrel was made of a dielectric 1 S material, whereas the tubular supporting element was kept under a potential of 25 kV, via electrical contacts.
Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims.
All publications, patents and patent applications mentioned in this specification are herein incorporated in their entirety by reference into the specification, to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated herein by reference. In addition, citation or identification of any reference in this application shall not be construed as an admthat such reference is available as prior art to the present invention.
Claims (229)
1. A stent assembly comprising an expensible tubular supporting element and at least one coat of electrospun polymer fibers, each of said at least one coat having a predetermined porosity, said at least one coat including at least one pharmaceutical agent incorporated therein for delivery of said at least one pharmaceutical agent into a body vasculature during or after implantation of the stent assembly within said body vasculature.
2. The stent assembly of claim 1, wherein said expensible tubular supporting element is designed and constructed for dilating a constricted blood vessel in said body vasculature.
3. The stent assembly of claim 1, wherein each of said at least one coat is independently a tubular structure.
4. The stent assembly of claim 2, wherein said at least one pharmaceutical agent serves for treating at least one disorder in said blood vessel.
5. The stent assembly of claim 4, wherein said at least one disorder comprises an injury inflicted on tissues of said blood vessel upon implantation of the stent assembly therein.
6. The stent assembly of claim 4, wherein said at least one disorder is selected from the group consisting of restenosis and in-stent stenosis.
7. The stent assembly of claim 4, wherein said at least one disorder is hyper cell proliferation.
8. The stent assembly of claim 1, wherein said at least one coat and said at least one pharmaceutical agent are configured and designed so as to provide a predetermined sustained release rate for effecting said delivery.
9. The stent assembly of claim 1, wherein said at least one coat and said at least one pharmaceutical agent are configured and designed so as to provide a predetermined duration of said delivery.
10. The stent assembly of claim 1, wherein said delivery is by diffusion.
11. The stent assembly of claim 10, wherein said delivery is initiated by a radial stretch of said at least one coat, said radial stretch is caused by an expansion of said expensible tubular supporting element.
12. The stent assembly of claim 1, wherein said expensible tubular supporting element comprises a deformable mesh of metal wires.
13. The stent assembly of claim 1, wherein said expensible tubular supporting element comprises a deformable mesh of stainless steel wires.
14. The stent assembly of claim 1, wherein said at least one coat comprises an inner coat and an outer coat.
15. The stent assembly of claim 14, wherein said inner coat comprises a layer lining an inner surface of said expensible tubular supporting element.
16. The stent assembly of claim 14, wherein said outer coat comprises a layer covering an outer surface of said expensible tubular supporting element.
17. The stent assembly of claim 1, wherein said electrospun polymer fibers are made of a biocompatible polymer.
18. The stent assembly of claim 1, wherein at least a portion of said electrospun polymer fibers is made of a biodegradable polymer.
19. The stent assembly of claim 1, wherein at least a portion of said electrospun polymer fibers is made of a biostable polymer.
20. The stent assembly of claim 1, wherein at least a portion of said electrospun polymer fibers is made of a combination of a biodegradable polymer and a biostable polymer.
21. The stent assembly of claim 1, wherein said electrospun polymer fibers are manufactured from a liquefied polymer.
22. The stent assembly of claim 21, wherein said at least one pharmaceutical agent is dissolved in said liquefied polymer.
23. The stent assembly of claim 21, wherein said at least one pharmaceutical agent is suspended in said liquefied polymer.
24. The stent assembly of claim 1, wherein said at least one pharmaceutical agent is constituted by compact objects distributed between said electrospun polymer fibers of said at least one coat.
25. The stent assembly of claim 24, wherein said compact objects are capsules.
26. The stent assembly of claim 1, wherein said at least one pharmaceutical agent is constituted by particles embedded in said electrospun polymer fibers.
27. The stent assembly of claim 1, wherein said at least one coat includes an adhesion layer.
28. The stent assembly of claim 27, wherein said adhesion layer is impervious adhesion layer.
29. The stent assembly of claim 27, wherein said adhesion layer is formed from electrospun polymer fibers.
30. The stent assembly of claim 1, wherein said electrospun polymer fibers are selected from the group consisting of polyethylene-terephtalat fibers and polyurethane fibers.
31. The stent assembly of claim 1, wherein said at least one pharmaceutical agent comprises heparin or heparin derivative.
32. The stent assembly of claim 1, wherein said at least one pharmaceutical agent comprises a radioactive compound.
33. The stent assembly of claim 1, wherein said at least one pharmaceutical agent comprises silver sulfadiazine.
34. The stent assembly of claim 1, wherein said at least one pharmaceutical agent comprises an antiproliferative drug.
35. The stent assembly of claim 1, wherein said at least one pharmaceutical agent comprises an anticoagulant drug.
36. The stent assembly of claim 12, wherein said at least one coat exposes gaps between said metal wires and exclusively covers said metal wires.
37. The stent assembly of claim 12, wherein said at least one coat substantially covers both gaps between said metal wires and said metal wires.
38. A method of producing a stent assembly, the method comprising:
(a) electrospinning a first liquefied polymer onto an expensible tubular supporting element, thereby coating said tubular supporting element with a first coat having a predetermined porosity; and (b) incorporating at least one pharmaceutical agent into said first coat.
(a) electrospinning a first liquefied polymer onto an expensible tubular supporting element, thereby coating said tubular supporting element with a first coat having a predetermined porosity; and (b) incorporating at least one pharmaceutical agent into said first coat.
39. The method of claim 38, wherein said at least one pharmaceutical agent is mixed with said liquefied polymer prior to said step of electrospinning, hence said step of incorporating said at least one pharmaceutical agent into said first coat is concomitant with said electrospinning.
40. The method of claim 39, wherein said at least one pharmaceutical agent is dissolved in said in said liquefied polymer.
41. The method of claim 39, wherein said at least one pharmaceutical agent is suspended in said liquefied polymer.
42. The method of claim 39, wherein said at least one pharmaceutical agent is constituted by particles embedded in polymer fibers produced during said step of electrospinning.
43. The method of claim 38, wherein said step of incorporating at least one pharmaceutical agent into said first coat comprises constituting said at least one pharmaceutical agent into compact objects, and distributing said compact objects between polymer fibers produced during said step of electrospinning.
44. The method of claim 43, wherein said compact objects are capsules.
45. The method of claim 43, wherein said compact objects are in a powder form.
46. The method of claim 43, wherein said distributing of said compact objects is by spraying.
47. The method of claim 38, wherein said expensible tubular supporting element comprises a deformable mesh of metal wires.
48. The method of claim 38, wherein said expensible tubular supporting element comprises a deformable mesh of stainless steel wires.
49. The method of claim 38, wherein said coat is of a tubular structure.
50. The method of claim 38, further comprising mounting said tubular supporting element onto a rotating mandrel, prior to said step (a).
51. The method of claim 50, further comprising electrospinning a second liquefied polymer onto said mandrel, prior to said step (a), hence providing an inner coat.
52. The method of claim 38, further comprising electrospinning at least one additional liquefied polymer onto said first coat, hence providing at least one additional coat.
53. The method of claim 38, further comprising providing at least one adhesion layer onto said tubular supporting element.
54. The method of claim 51, further comprising providing at least one adhesion layer onto at least one coat.
55. The method of claim 53, wherein said adhesion layer is an impervious adhesion layer.
56. The method of claim 54, wherein said adhesion layer is an impervious adhesion layer.
57. The method of claim 53, wherein said providing at least one adhesion layer is by electrospinning.
58. The method of claim 54, wherein said providing at least one adhesion layer is by electrospinning.
59. The method of claim 50, wherein said electrospinning step comprises:
(i) charging said liquefied polymer thereby producing a charged liquefied polymer;
(ii) subjecting said charged liquefied polymer to a first electric field; and (iii) dispensing said charged liquefied polymers within said first electric field in a direction of said mandrel.
(i) charging said liquefied polymer thereby producing a charged liquefied polymer;
(ii) subjecting said charged liquefied polymer to a first electric field; and (iii) dispensing said charged liquefied polymers within said first electric field in a direction of said mandrel.
60. The method of claim 59, wherein said mandrel is of a conductive material.
61. The method of claim 60, wherein said first electric field is defined between said mandrel and a dispensing electrode being at a first potential relative to said mandrel.
62. The method of claim 60, further comprising providing a second electric field defined by a subsidiary electrode being at a second potential relative to said mandrel, said second electric field being for modifying said first electric field.
63. The method of claim 62, wherein said subsidiary electrode serves for reducing non-unifomities in said first electric field.
64. The method of claim 62, wherein said subsidiary electrode serves for controlling fiber orientation of each of said coats.
65. The method of claim 59, wherein said mandrel is of a dielectric material.
66. The method of claim 59, wherein said tubular supporting element serves as a mandrel.
67. The method of claim 65, wherein said first electric field is defined between said tubular supporting element and a dispensing electrode being at a first potential relative to said tubular supporting element.
68. The method of claim 65, further comprising providing a second electric field defined by a subsidiary electrode being at a second potential relative to said tubular supporting element, said second electric field being for modifying said first electric field.
69. The method of claim 68, wherein said subsidiary electrode serves for reducing non-uniformities in said first electric field.
70. The method of claim 68, wherein said subsidiary electrode serves for controlling fiber orientation of each of said coats.
71. The method of claim 38, wherein said first liquefied polymer is a biocompatible liquefied polymer.
72. The method of claim 38, wherein said first liquefied polymer is a biodegradable liquefied polymer.
73. The method of claim 38, wherein said first liquefied polymer is a biostable liquefied polymer.
74. The method of claim 38, wherein first liquefied polymer is a combination of a biodegradable liquefied polymer and a biostable liquefied polymer.
75. The method of claim 51, wherein said second liquefied polymer is a biocompatible liquefied polymer.
76. The method of claim 51, wherein said second liquefied polymer is a biodegradable liquefied polymer.
77. The method of claim 51, wherein said second liquefied polymer is a biostable liquefied polymer.
78. The method of claim 51, wherein said second liquefied polymer is a combination of a biodegradable liquefied polymer and a biostable liquefied polymer.
79. The method of claim 52, wherein each of said at least one additional liquefied polymer is independently a biocompatible liquefied polymer.
80. The method of claim 52, wherein each of said at least one additional liquefied polymer is independently biodegradable liquefied polymer.
81. The method of claim 52, wherein each of said at least one additional liquefied polymer is independently a biostable liquefied polymer.
82. The method of claim 52, wherein each of said at least one additional liquefied polymer is independently a combination of a biodegradable liquefied polymer and a biostable liquefied polymer.
83. The method of claim 38, wherein said at least one pharmaceutical agent is heparin.
84. The method of claim 38, wherein said at least one pharmaceutical agent is a radioactive compound.
85. The method of claim 38, wherein said at least one pharmaceutical agent is silver sulfadiazine.
86. The method of claim 50, further comprising heating said mandrel prior to, during or subsequent to said step of electrospinning.
87. The method of claim 86, wherein said heating of said mandrel is selected from the group consisting of external heating and internal heating.
88. The method of claim 87, wherein said external heating is by at least one infrared radiator.
89. The method of claim 88, wherein said at least one infrared radiator is an infrared lamp.
90. The method of claim 87, wherein said internal heating is by a built-in heater.
91. The method of claim 90, wherein said built-in heater is an Ohmic built-in heater.
92. The method of claim 50, further comprising removing the stent assembly from said mandrel.
93. The method of claim 92, further comprising dipping the stent assembly in a vapor.
94. The method of claim 93, further comprising heating said vapor.
95. The method of claim 92, wherein said vapor is saturated a DMF
vapor.
vapor.
96. The method of claim 38, further comprising exposing the stent assembly to a partial vacuum processing.
97. A method of treating a constricted blood vessel, the method comprising placing a stent assembly in the constricted blood vessel, said stent assembly comprises an expensible tubular supporting element and at least one coat of electrospun polymer fibers, each of said at least one coat having a predetermined porosity, said at least one coat including at least one pharmaceutical agent incorporated therein for delivery of said at least one pharmaceutical agent into a body vasculature during or after implantation of the stent assembly within said body vasculature.
98. The method of claim 97, wherein said expensible tubular supporting element is designed and constructed for dilating a constricted blood vessel in said body vasculature.
99. The method of claim 97, wherein each of said at least one coat is independently a tubular structure.
100. The method of claim 98, wherein said at least one pharmaceutical agent serves for treating at least one disorder in said blood vessel.
101. The method of claim 100, wherein said at least one disorder comprises an injury inflicted on tissues of said blood vessel upon implantation of the stent assembly therein.
102. The method of claim 100, wherein said at least one disorder is selected from the group consisting of restenosis and in-stent stenosis.
103. The method of claim 100, wherein said at least one disorder is hyper cell proliferation.
104. The method of claim 97, wherein said at least one coat and said at least one pharmaceutical agent are configured and designed so as to provide a predetermined sustained release rate for effecting said delivery.
105. The method of claim 97, wherein said at least one coat and said at least one pharmaceutical agent are configured and designed so as to provide a predetermined duration of said delivery.
106. The method of claim 97, wherein said delivery is by diffusion.
107. The method of claim 106, wherein said delivery is initiated by a radial stretch of said at least one coat, said radial stretch is caused by an expansion of said expensible tubular supporting element.
108. The method of claim 97, wherein said expensible tubular supporting element comprises a deformable mesh of metal wires.
109. The method of claim 97, wherein said expensible tubular supporting element comprises a deformable mesh of stainless steel wires.
110. The method of claim 97, wherein said at least one coat comprises an inner coat and an outer coat.
111. The method of claim 110, wherein said inner coat comprises a layer lining an inner surface of said expensible tubular supporting element.
112. The method of claim 110, wherein said outer coat comprises a layer covering an outer surface of said expensible tubular supporting element.
113. The method of claim 97, wherein said electrospun polymer fibers are made of a biocompatible polymer.
114. The method of claim 97, wherein at least a portion of said electrospun polymer fibers is made of a biodegradable polymer.
115. The method of claim 97, wherein at least a portion of said electrospun polymer fibers is made of a biostable polymer.
116. The method of claim 97, wherein at least a portion of said electrospun polymer fibers is made of a combination of a biodegradable polymer and a biostable polymer.
117. The method of claim 97, wherein said electrospun polymer fibers are manufactured from a liquefied polymer.
118. The method of claim 117, wherein said at least one pharmaceutical agent is dissolved in said liquefied polymer.
119. The method of claim 117, wherein said at least one pharmaceutical agent is suspended in said liquefied polymer.
120. The method of claim 97, wherein said at least one pharmaceutical agent is constituted by compact objects distributed between said electrospun polymer fibers of said at least one coat.
121. The method of claim 120, wherein said compact objects are capsules.
122. The method of claim 97, wherein said at least one pharmaceutical agent is constituted by particles embedded in said electrospun polymer fibers.
123. The method of claim 97, wherein said at least one coat includes an adhesion layer.
124. The method of claim 123, wherein said adhesion layer is impervious adhesion layer.
125. The method of claim 123, wherein said adhesion layer is formed from electrospun polymer fibers.
126. The method of claim 97, wherein said electrospun polymer fibers are selected from the group consisting of polyethylene-terephtalat fibers and polyurethane fibers.
127. The method of claim 97, wherein said at least one pharmaceutical agent comprises heparin or heparin derivative.
128. The method of claim 97, wherein said at least one pharmaceutical agent comprises a radioactive compound.
129. The method of claim 97, wherein said at least one pharmaceutical agent comprises silver sulfadiazine.
130. The method of claim 97, wherein said at least one pharmaceutical agent comprises an antiproliferative drug.
131. The method of claim 97, wherein said at least one pharmaceutical agent comprises an anticoagulant drug.
132. The method of claim 108, wherein said at least one coat exposes gaps between said metal wires and exclusively covers said metal wires.
133. The method of claim 108, wherein said at least one coat substantially covers both gaps between said metal wires and said metal wires.
134. A method of dilating a constricted blood vessel, the method comprising:
(a) providing a stent assembly comprises an expensible tubular supporting element and at least one coat of electrospun polymer fibers, each of said at least one coat having a predetermined porosity, said at least one coat including at least one pharmaceutical agent incorporated therein;
(b) placing said stent assembly to a constricted region in the constricted blood vessel; and (c) radially expanding said stent assembly within the blood vessel so as to dilate said constricted region and to allow blood flow through the blood vessel.
(a) providing a stent assembly comprises an expensible tubular supporting element and at least one coat of electrospun polymer fibers, each of said at least one coat having a predetermined porosity, said at least one coat including at least one pharmaceutical agent incorporated therein;
(b) placing said stent assembly to a constricted region in the constricted blood vessel; and (c) radially expanding said stent assembly within the blood vessel so as to dilate said constricted region and to allow blood flow through the blood vessel.
135. The method of claim 134, wherein said expensible tubular supporting element is designed and constructed for dilating a constricted blood vessel in said body vasculature.
136. The method of claim 134, wherein each of said at least one coat is independently a tubular structure.
137. The method of claim 135, wherein said at least one pharmaceutical agent serves for treating at least one disorder in said blood vessel.
138. The method of claim 137, wherein said at least one disorder comprises an injury inflicted on tissues of said blood vessel upon implantation of the stent assembly therein.
139. The method of claim 137, wherein said at least one disorder is selected from the group consisting of restenosis and in-stent stenosis.
140. The method of claim 137, wherein said at least one disorder is hyper cell proliferation.
141. The method of claim 134, wherein said at least one coat and said at least one pharmaceutical agent are configured and designed so as to provide a predetermined sustained release rate for effecting said delivery.
142. The method of claim 134, wherein said at least one coat and said at least one pharmaceutical agent are configured and designed so as to provide a predetermined duration of said delivery.
143. The method of claim 134, wherein said delivery is by diffusion.
144. The method of claim 143, wherein said delivery is initiated by a radial stretch of said at least one coat, said radial stretch is caused by an expansion of said expensible tubular supporting element.
145. The method of claim 134, wherein said expensible tubular supporting element comprises a deformable mesh of metal wires.
146. The method of claim 134, wherein said expensible tubular supporting element comprises a deformable mesh of stainless steel wires.
147. The method of claim 134, wherein said at least one coat comprises an inner coat and an outer coat.
148. The method of claim 147, wherein said inner coat comprises a layer lining an inner surface of said expensible tubular supporting element.
149. The method of claim 147, wherein said outer coat comprises a layer covering an outer surface of said expensible tubular supporting element.
150. The method of claim 134, wherein said electrospun polymer fibers are made of a biocompatible polymer.
151. The method of claim 134, wherein at least a portion of said electrospun polymer fibers is made of a biodegradable polymer.
152. The method of claim 134, wherein at least a portion of said electrospun polymer fibers is made of a biostable polymer.
153. The method of claim 134, wherein at least a portion of said electrospun polymer fibers is made of a combination of a biodegradable polymer and a biostable polymer.
154. The method of claim 134, wherein said electrospun polymer fibers are manufactured from a liquefied polymer.
155. The method of claim 154, wherein said at least one pharmaceutical agent is dissolved in said liquefied polymer.
156. The method of claim 154, wherein said at least one pharmaceutical agent is suspended in said liquefied polymer.
157. The method of claim 134, wherein said at least one pharmaceutical agent is constituted by compact objects distributed between said electrospun polymer fibers of said at least one coat.
158. The method of claim 157, wherein said compact objects are capsules.
159. The method of claim 134, wherein said at least one pharmaceutical agent is constituted by particles embedded in said electrospun polymer fibers.
160. The method of claim 134, wherein said at least one coat includes an adhesion layer.
161. The method of claim 160, wherein said adhesion layer is impervious adhesion layer.
162. The method of claim 160, wherein said adhesion layer is formed from electrospun polymer fibers.
163. The method of claim 134, wherein said electrospun polymer fibers are selected from the group consisting of polyethylene-terephtalat fibers and polyurethane fibers.
164. The method of claim 134, wherein said at least one pharmaceutical agent comprises heparin or heparin derivative.
165. The method of claim 134, wherein said at least one pharmaceutical agent comprises a radioactive compound.
166. The method of claim 134, wherein said at least one pharmaceutical agent comprises silver sulfadiazine.
167. The method of claim 134, wherein said at least one pharmaceutical agent comprises an antiproliferative drug.
168. The method of claim 134, wherein said at least one pharmaceutical agent comprises an anticoagulant drug.
169. The method of claim 145, wherein said at least one coat exposes gaps between said metal wires and exclusively covers said metal wires.
170. The method of claim 145, wherein said at least one coat substantially covers both gaps between said metal wires and said metal wires.
171. A method of coating a medical implant, implantable in a body, and loading the medical implant with a pharmaceutical agent, the method comprising:
(a) electrospinning a first liquefied polymer onto the medical implant, thereby coating the medical implant with a first coat having a predetermined porosity; and (b) incorporating at least one pharmaceutical agent into said first coat;
thereby providing a coated medical implant loaded with the at least one pharmaceutical agent.
(a) electrospinning a first liquefied polymer onto the medical implant, thereby coating the medical implant with a first coat having a predetermined porosity; and (b) incorporating at least one pharmaceutical agent into said first coat;
thereby providing a coated medical implant loaded with the at least one pharmaceutical agent.
172. The method of claim 171, wherein the medical implant is selected from the group consisting of a graft, a patch and a valve.
173. The method of claim 171, wherein said at least one pharmaceutical agent is mixed with a liquefied polymer prior to said step of electrospinning, hence said step of incorporating said at least one pharmaceutical agent into said first coat is concomitant with said electrospinning.
174. The method of claim 173, wherein said at least one pharmaceutical agent is dissolved in said in said first liquefied polymer.
175. The method of claim 173, wherein said at least one pharmaceutical agent is suspended in said first liquefied polymer.
176. The method of claim 173, wherein said at least one pharmaceutical agent is constituted by particles embedded in polymer fibers produced during said step of electrospinning.
177. The method of claim 171, wherein said step of incorporating at least one pharmaceutical agent into said first coat comprises constituting said at least one pharmaceutical agent into compact objects, and distributing said compact objects between polymer fibers produced during said step of electrospinning.
178. The method of claim 177, wherein said compact objects are capsules.
179. The method of claim 177, wherein said compact objects are in a powder form.
180. The method of claim 177, wherein said distributing of said compact objects is by spraying.
181. The method of claim 171, wherein said coat is of a tubular structure.
182. The method of claim 171, further comprising rotating the medical implant during said step (a).
183. The method of claim 182, wherein said rotating comprises connecting the medical implant to a rotating mandrel.
184. The method of claim 183, further comprising electrospinning a second liquefied polymer onto said mandrel, prior to said step (a), hence providing an inner coat.
185. The method of claim 171, further comprising electrospinning at least one additional liquefied polymer onto said first coat, hence providing at least one additional coat.
186. The method of claim 171, further comprising providing at least one adhesion layer onto the medical implant.
187. The method of claim 184, further comprising providing at least one adhesion layer onto at least one coat.
188. The method of claim 186, wherein said adhesion layer is an impervious adhesion layer.
189. The method of claim 187, wherein said adhesion layer is an impervious adhesion layer.
190. The method of claim 186, wherein said providing at least one adhesion layer is by electrospinning.
191. The method of claim 187, wherein said providing at least one adhesion layer is by electrospinning.
192. The method of claim 183, wherein said electrospinning step comprises:
(i) charging said liquefied polymer thereby producing a charged liquefied polymer;
(ii) subjecting said charged liquefied polymer to a first electric field; and (iii) dispensing said charged liquefied polymers within said first electric field in a direction of said mandrel.
(i) charging said liquefied polymer thereby producing a charged liquefied polymer;
(ii) subjecting said charged liquefied polymer to a first electric field; and (iii) dispensing said charged liquefied polymers within said first electric field in a direction of said mandrel.
193. The method of claim 192, wherein said mandrel is of a conductive material.
194. The method of claim 193, wherein said first electric field is defined between said mandrel and a dispensing electrode being at a first potential relative to said mandrel.
195. The method of claim 193, further comprising providing a second electric field defined by a subsidiary electrode being at a second potential relative to said mandrel, said second electric field being for modifying said first electric field.
196. The method of claim 195, wherein said subsidiary electrode serves for reducing non-uniformities in said first electric field.
197. The method of claim 195, wherein said subsidiary electrode serves for controlling fiber orientation of each of said coats generated upon the medical implant.
198. The method of claim 192, wherein said mandrel is of a dielectric material.
199. The method of claim 192, wherein the medical implant serves as a mandrel.
200. The method of claim 198, wherein said first electric field is defined between the medical implant and a dispensing electrode being at a first potential relative to the medical implant.
201. The method of claim 198, further comprising providing a second electric field defined by a subsidiary electrode being at a second potential relative to the medical implant, said second electric field being for modifying said first electric field.
202. The method of claim 201, wherein said subsidiary electrode serves for reducing non-uniformities in said first electric field.
203. The method of claim 201, wherein said subsidiary electrode serves for controlling fiber orientation of each of said coats generated upon the medical implant.
204. The method of claim 171, wherein said first liquefied polymer is a biocompatible liquefied polymer.
205. The method of claim 171, wherein said first liquefied polymer is a biodegradable liquefied polymer.
206. The method of claim 171, wherein said first liquefied polymer is a biostable liquefied polymer.
207. The method of claim 171, wherein first liquefied polymer is a combination of a biodegradable liquefied polymer and a biostable liquefied polymer.
208. The method of claim 184, wherein said second liquefied polymer is a biocompatible liquefied polymer.
209. The method of claim 184, wherein said second liquefied polymer is a biodegradable liquefied polymer.
210. The method of claim 184, wherein said second liquefied polymer is a biostable liquefied polymer.
211. The method of claim 184, wherein said second liquefied polymer is a combination of a biodegradable liquefied polymer and a biostable liquefied polymer.
212. The method of claim 185, wherein each of said at least one additional liquefied polymer is independently a biocompatible liquefied polymer.
213. The method of claim 185, wherein each of said at least one additional liquefied polymer is independently a biodegradable liquefied polymer.
214. The method of claim 185, wherein each of said at least one additional liquefied polymer is independently a biostable liquefied polymer.
215. The method of claim 185, wherein each of said at least one additional liquefied polymer is independently a combination of a biodegradable liquefied polymer and a biostable liquefied polymer.
216. The method of claim 171, wherein said at least one pharmaceutical agent is Heparin.
217. The method of claim 171, wherein said at least one pharmaceutical agent is a radioactive compound.
218. The method of claim 171, wherein said at least one pharmaceutical agent is silver sulfadiazine.
219. The method of claim 183, further comprising heating said mandrel prior to, during or subsequent to said step of electrospinning.
220. The method of claim 219, wherein said heating of said mandrel is selected from the group consisting of external heating and internal heating.
221. The method of claim 220, wherein said external heating is by at least one infrared radiator.
222. The method of claim 221, wherein said at least one infrared radiator is an infrared lamp.
223. The method of claim 220, wherein said internal heating is by a built-in heater.
224. The method of claim 223, wherein said built-in heater is an Ohmic built-in heater.
225. The method of claim 183, further comprising removing the coated medical implant from said mandrel.
226. The method of claim 225, further comprising dipping the coated medical implant in a vapor.
227. The method of claim 226, further comprising heating said vapor.
228. The method of claim 225, wherein said vapor is saturated a DMF
vapor.
vapor.
229. The method of claim 171, further comprising exposing the coated medical implant to a partial vacuum processing.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25632300P | 2000-12-19 | 2000-12-19 | |
US60/256,323 | 2000-12-19 | ||
US27695601P | 2001-03-20 | 2001-03-20 | |
US60/276,956 | 2001-03-20 | ||
US09/982,017 | 2001-10-19 | ||
US09/982,017 US20020084178A1 (en) | 2000-12-19 | 2001-10-19 | Method and apparatus for manufacturing polymer fiber shells via electrospinning |
PCT/IL2001/001171 WO2002049535A2 (en) | 2000-12-19 | 2001-12-17 | Medicated polymer-coated stent assembly |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2432159A1 true CA2432159A1 (en) | 2002-06-27 |
Family
ID=27400942
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002432156A Abandoned CA2432156A1 (en) | 2000-12-19 | 2001-12-17 | Method and apparatus for manufacturing polymer fiber shells via electrospinning |
CA2432164A Expired - Fee Related CA2432164C (en) | 2000-12-19 | 2001-12-17 | Improved vascular prosthesis and method for production thereof |
CA002432159A Abandoned CA2432159A1 (en) | 2000-12-19 | 2001-12-17 | Medicated polymer-coated stent assembly |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002432156A Abandoned CA2432156A1 (en) | 2000-12-19 | 2001-12-17 | Method and apparatus for manufacturing polymer fiber shells via electrospinning |
CA2432164A Expired - Fee Related CA2432164C (en) | 2000-12-19 | 2001-12-17 | Improved vascular prosthesis and method for production thereof |
Country Status (12)
Country | Link |
---|---|
US (5) | US20020084178A1 (en) |
EP (3) | EP1578306A2 (en) |
JP (3) | JP2005507464A (en) |
CN (3) | CN1635861A (en) |
AT (2) | ATE460903T1 (en) |
AU (4) | AU2002216342A1 (en) |
CA (3) | CA2432156A1 (en) |
DE (2) | DE60141710D1 (en) |
HK (1) | HK1080347A1 (en) |
IL (5) | IL156512A0 (en) |
MX (3) | MXPA03005552A (en) |
WO (3) | WO2002049536A2 (en) |
Families Citing this family (285)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040267349A1 (en) | 2003-06-27 | 2004-12-30 | Kobi Richter | Amorphous metal alloy medical devices |
US8382821B2 (en) | 1998-12-03 | 2013-02-26 | Medinol Ltd. | Helical hybrid stent |
US20070219642A1 (en) * | 1998-12-03 | 2007-09-20 | Jacob Richter | Hybrid stent having a fiber or wire backbone |
US7615373B2 (en) * | 1999-02-25 | 2009-11-10 | Virginia Commonwealth University Intellectual Property Foundation | Electroprocessed collagen and tissue engineering |
WO2002018441A2 (en) * | 2000-09-01 | 2002-03-07 | Virginia Commonwealth University Intellectual Property Foundation | Electroprocessed fibrin-based matrices and tissues |
US20020081732A1 (en) * | 2000-10-18 | 2002-06-27 | Bowlin Gary L. | Electroprocessing in drug delivery and cell encapsulation |
US6743273B2 (en) | 2000-09-05 | 2004-06-01 | Donaldson Company, Inc. | Polymer, polymer microfiber, polymer nanofiber and applications including filter structures |
US7270693B2 (en) * | 2000-09-05 | 2007-09-18 | Donaldson Company, Inc. | Polymer, polymer microfiber, polymer nanofiber and applications including filter structures |
US20020084178A1 (en) * | 2000-12-19 | 2002-07-04 | Nicast Corporation Ltd. | Method and apparatus for manufacturing polymer fiber shells via electrospinning |
US20070031607A1 (en) * | 2000-12-19 | 2007-02-08 | Alexander Dubson | Method and apparatus for coating medical implants |
RU2300543C2 (en) * | 2001-05-31 | 2007-06-10 | Дональдсон Компани, Инк. | Fine fiber compositions, methods for preparation thereof, and a method of manufacturing fine-fiber material |
WO2003087443A1 (en) * | 2002-04-11 | 2003-10-23 | Secant Medical, Inc. | Covering process using electrospinning of very small fibers |
JP5445649B2 (en) * | 2002-08-23 | 2014-03-19 | 独立行政法人国立循環器病研究センター | Stent |
GB0223870D0 (en) * | 2002-10-14 | 2002-11-20 | Cathnet Science Holding As | Stent assembly |
US6949916B2 (en) * | 2002-11-12 | 2005-09-27 | Power-One Limited | System and method for controlling a point-of-load regulator |
US20040098023A1 (en) * | 2002-11-15 | 2004-05-20 | Scimed Life Systems, Inc. | Embolic device made of nanofibers |
JP4047739B2 (en) * | 2003-02-04 | 2008-02-13 | 日本バイリーン株式会社 | Electrostatic spinning method and electrostatic spinning apparatus |
JP4047744B2 (en) * | 2003-02-27 | 2008-02-13 | 日本バイリーン株式会社 | Electrostatic spinning method and electrostatic spinning apparatus |
JP2004256974A (en) * | 2003-02-27 | 2004-09-16 | Japan Vilene Co Ltd | Method for electrospinning and device for electrospinning |
US7658747B2 (en) | 2003-03-12 | 2010-02-09 | Nmt Medical, Inc. | Medical device for manipulation of a medical implant |
JP4496360B2 (en) * | 2003-04-24 | 2010-07-07 | 国立大学法人九州大学 | Medical Polymer Nano / Microfiber |
US7452374B2 (en) * | 2003-04-24 | 2008-11-18 | Maquet Cardiovascular, Llc | AV grafts with rapid post-operative self-sealing capabilities |
JP4971580B2 (en) * | 2003-06-05 | 2012-07-11 | テルモ株式会社 | Stent and method for manufacturing stent |
US9039755B2 (en) | 2003-06-27 | 2015-05-26 | Medinol Ltd. | Helical hybrid stent |
US9155639B2 (en) | 2009-04-22 | 2015-10-13 | Medinol Ltd. | Helical hybrid stent |
FR2858543B1 (en) * | 2003-08-08 | 2006-02-03 | Assist Publ Hopitaux De Paris | AORTIC AND ANCILLARY RING FOR ITS INSTALLATION |
CZ20032421A3 (en) * | 2003-09-08 | 2004-11-10 | Technická univerzita v Liberci | Process for producing nanofibers of polymer solution by electrostatic spinning and apparatus for making the same |
EP1677849A1 (en) * | 2003-10-14 | 2006-07-12 | Cube Medical A/S | A balloon for use in angioplasty |
DE10350287A1 (en) | 2003-10-24 | 2005-05-25 | Deutsche Institute für Textil- und Faserforschung Stuttgart - Stiftung des öffentlichen Rechts | Cardiovascular implant, for use as a vascular or heart valve replacement, comprises a non-resorbable polymer formed as a microfiber fleece that allows colonization by a cells |
WO2005042813A1 (en) * | 2003-10-30 | 2005-05-12 | Clean Air Technology Corp. | Electrostatic spinning equipment and method of preparing nano fiber using the same |
WO2005055834A1 (en) * | 2003-11-20 | 2005-06-23 | Nmt Medical, Inc. | Device, with electrospun fabric, for a percutaneous transluminal procedure, and methods thereof |
DE60331264D1 (en) * | 2003-12-30 | 2010-03-25 | Kim Hag Yong | |
WO2005065578A2 (en) * | 2004-01-06 | 2005-07-21 | Nicast Ltd. | Vascular prosthesis with anastomotic member |
US20050192626A1 (en) | 2004-01-30 | 2005-09-01 | Nmt Medical, Inc. | Devices, systems, and methods for closure of cardiac openings |
DE602004026116D1 (en) * | 2004-01-30 | 2010-04-29 | Kim Hak Yong | FROM THE BOTTOM UP WORKING ELECTROSPIN DEVICE |
EP1718245A4 (en) | 2004-02-12 | 2008-03-19 | Univ Akron | Mechanically attached medical device coatings |
US20060142838A1 (en) * | 2004-12-29 | 2006-06-29 | Masoud Molaei | Medical devices including metallic films and methods for loading and deploying same |
US8591568B2 (en) * | 2004-03-02 | 2013-11-26 | Boston Scientific Scimed, Inc. | Medical devices including metallic films and methods for making same |
US20050197687A1 (en) * | 2004-03-02 | 2005-09-08 | Masoud Molaei | Medical devices including metallic films and methods for making same |
US8998973B2 (en) * | 2004-03-02 | 2015-04-07 | Boston Scientific Scimed, Inc. | Medical devices including metallic films |
US7901447B2 (en) * | 2004-12-29 | 2011-03-08 | Boston Scientific Scimed, Inc. | Medical devices including a metallic film and at least one filament |
US8632580B2 (en) * | 2004-12-29 | 2014-01-21 | Boston Scientific Scimed, Inc. | Flexible medical devices including metallic films |
US8992592B2 (en) * | 2004-12-29 | 2015-03-31 | Boston Scientific Scimed, Inc. | Medical devices including metallic films |
ES2327545T3 (en) * | 2004-03-16 | 2009-10-30 | University Of Delaware | FIBERS, TEXTILE MATERIALS AND ACTIVE AND ADAPTATION PHOTOCROMIC MEMBRANES. |
JP4312090B2 (en) * | 2004-03-18 | 2009-08-12 | 日本バイリーン株式会社 | Method for manufacturing fiber assembly and apparatus for manufacturing fiber assembly by electrostatic spinning |
WO2005095684A1 (en) * | 2004-03-25 | 2005-10-13 | Massachusetts Institute Of Technology | Production of submicron diameter fibers by two-fluid electrospinning process |
JP2005278993A (en) * | 2004-03-30 | 2005-10-13 | Terumo Corp | Stent for indwelling in living body, and production method of the same |
US7297305B2 (en) * | 2004-04-08 | 2007-11-20 | Research Triangle Institute | Electrospinning in a controlled gaseous environment |
US7134857B2 (en) * | 2004-04-08 | 2006-11-14 | Research Triangle Institute | Electrospinning of fibers using a rotatable spray head |
US7592277B2 (en) * | 2005-05-17 | 2009-09-22 | Research Triangle Institute | Nanofiber mats and production methods thereof |
US7762801B2 (en) | 2004-04-08 | 2010-07-27 | Research Triangle Institute | Electrospray/electrospinning apparatus and method |
NL1026076C2 (en) | 2004-04-29 | 2005-11-01 | Univ Eindhoven Tech | Molded part manufactured by means of electro-spinning and a method for the manufacture thereof as well as the use of such a molded part. |
JP2007534389A (en) * | 2004-04-29 | 2007-11-29 | キューブ・メディカル・アクティーゼルスカブ | Balloon used for angiogenesis |
US20060012084A1 (en) * | 2004-07-13 | 2006-01-19 | Armantrout Jack E | Electroblowing web formation process |
JP4964134B2 (en) | 2004-08-31 | 2012-06-27 | シー・アール・バード・インコーポレーテッド | Self-sealing PTFE graft with torsion resistance |
US9801982B2 (en) | 2004-09-28 | 2017-10-31 | Atrium Medical Corporation | Implantable barrier device |
US9012506B2 (en) | 2004-09-28 | 2015-04-21 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
US9592324B2 (en) | 2006-11-06 | 2017-03-14 | Atrium Medical Corporation | Tissue separating device with reinforced support for anchoring mechanisms |
US8858978B2 (en) | 2004-09-28 | 2014-10-14 | Atrium Medical Corporation | Heat cured gel and method of making |
US20060088596A1 (en) | 2004-09-28 | 2006-04-27 | Atrium Medical Corporation | Solubilizing a drug for use in a coating |
US9000040B2 (en) | 2004-09-28 | 2015-04-07 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
EP1804844A4 (en) * | 2004-09-29 | 2012-02-29 | Univ Singapore | A composite, method of producing the composite and uses of the same |
US7390760B1 (en) | 2004-11-02 | 2008-06-24 | Kimberly-Clark Worldwide, Inc. | Composite nanofiber materials and methods for making same |
US20060094320A1 (en) * | 2004-11-02 | 2006-05-04 | Kimberly-Clark Worldwide, Inc. | Gradient nanofiber materials and methods for making same |
US8029563B2 (en) * | 2004-11-29 | 2011-10-04 | Gore Enterprise Holdings, Inc. | Implantable devices with reduced needle puncture site leakage |
US7922761B2 (en) * | 2005-01-25 | 2011-04-12 | Nicast Ltd. | Artificial vascular prosthesis |
US10328032B2 (en) * | 2005-03-04 | 2019-06-25 | Biosurfaces, Inc. | Nanofibrous materials as drug, protein, or genetic release vehicles |
WO2006099107A2 (en) * | 2005-03-10 | 2006-09-21 | Massachusetts Institute Of Technology | Superhydrophobic fibers and methods of preparation and use thereof |
US7732427B2 (en) * | 2005-03-31 | 2010-06-08 | University Of Delaware | Multifunctional and biologically active matrices from multicomponent polymeric solutions |
US7737131B2 (en) * | 2005-03-31 | 2010-06-15 | University Of Delaware | Multifunctional and biologically active matrices from multicomponent polymeric solutions |
US8415325B2 (en) * | 2005-03-31 | 2013-04-09 | University Of Delaware | Cell-mediated delivery and targeted erosion of noncovalently crosslinked hydrogels |
US8367639B2 (en) | 2005-03-31 | 2013-02-05 | University Of Delaware | Hydrogels with covalent and noncovalent crosslinks |
US8871237B2 (en) | 2005-04-04 | 2014-10-28 | Technion Research & Development Foundation Limited | Medical scaffold, methods of fabrication and using thereof |
US7854760B2 (en) * | 2005-05-16 | 2010-12-21 | Boston Scientific Scimed, Inc. | Medical devices including metallic films |
US20090088828A1 (en) * | 2005-05-17 | 2009-04-02 | Nicast Ltd. | Electrically Charged Implantable Medical Device |
US8267993B2 (en) | 2005-06-09 | 2012-09-18 | Coroneo, Inc. | Expandable annuloplasty ring and associated ring holder |
CA2610896C (en) | 2005-06-17 | 2014-07-08 | C.R. Bard, Inc. | Vascular graft with kink resistance after clamping |
GB2427382A (en) * | 2005-06-21 | 2006-12-27 | Univ Sheffield | Electrospinning of fibres |
CN100531685C (en) * | 2005-07-20 | 2009-08-26 | 同济大学 | Tissue engineering blood vessel and method of construction in vitro |
FR2898502B1 (en) * | 2006-03-16 | 2012-06-15 | Sofradim Production | THREE DIMENSIONAL PROTHETIC FABRIC WITH RESORBABLE DENSE FACE |
US20070036842A1 (en) * | 2005-08-15 | 2007-02-15 | Concordia Manufacturing Llc | Non-woven scaffold for tissue engineering |
US7582247B2 (en) * | 2005-08-17 | 2009-09-01 | E. I. Du Pont De Nemours And Company | Electroblowing fiber spinning process |
US7465159B2 (en) * | 2005-08-17 | 2008-12-16 | E.I. Du Pont De Nemours And Company | Fiber charging apparatus |
US20070048351A1 (en) * | 2005-09-01 | 2007-03-01 | Prescient Medical, Inc. | Drugs coated on a device to treat vulnerable plaque |
EP1929074A4 (en) * | 2005-09-26 | 2009-09-02 | Hak-Yong Kim | Conjugate electrospinning devices, conjugate nonwoven and filament comprising nanofibers prepared by using the same |
US9278161B2 (en) | 2005-09-28 | 2016-03-08 | Atrium Medical Corporation | Tissue-separating fatty acid adhesion barrier |
US9427423B2 (en) | 2009-03-10 | 2016-08-30 | Atrium Medical Corporation | Fatty-acid based particles |
CA2626030A1 (en) | 2005-10-15 | 2007-04-26 | Atrium Medical Corporation | Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings |
US20070173787A1 (en) * | 2005-11-01 | 2007-07-26 | Huang Mark C T | Thin-film nitinol based drug eluting stent |
CA2626598A1 (en) | 2005-11-09 | 2007-05-18 | C.R. Bard Inc. | Grafts and stent grafts having a radiopaque marker |
KR20080083637A (en) * | 2005-11-28 | 2008-09-18 | 유니버시티 오브 델라웨어 | Method of solution preparation of polyolefin class polymers for electrospinning processing included |
EP1957695B1 (en) * | 2005-12-07 | 2011-02-09 | Ramot at Tel-Aviv University Ltd. | Drug-delivering composite structures |
US20070155273A1 (en) * | 2005-12-16 | 2007-07-05 | Cornell Research Foundation, Inc. | Non-woven fabric for biomedical application based on poly(ester-amide)s |
US20070148365A1 (en) * | 2005-12-28 | 2007-06-28 | Knox David E | Process and apparatus for coating paper |
JP4778797B2 (en) * | 2006-01-25 | 2011-09-21 | 株式会社Espinex | Nanofiber |
US20080220042A1 (en) * | 2006-01-27 | 2008-09-11 | The Regents Of The University Of California | Biomolecule-linked biomimetic scaffolds |
JP5249785B2 (en) * | 2006-01-27 | 2013-07-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Biomimetic scaffold |
US20070203564A1 (en) * | 2006-02-28 | 2007-08-30 | Boston Scientific Scimed, Inc. | Biodegradable implants having accelerated biodegradation properties in vivo |
US7737060B2 (en) * | 2006-03-31 | 2010-06-15 | Boston Scientific Scimed, Inc. | Medical devices containing multi-component fibers |
WO2008020326A2 (en) * | 2006-04-07 | 2008-02-21 | Victor Barinov | Controlled electrospinning of fibers |
US7689291B2 (en) * | 2006-05-01 | 2010-03-30 | Cardiac Pacemakers, Inc. | Lead with fibrous matrix coating and methods related thereto |
JP2008011942A (en) * | 2006-07-03 | 2008-01-24 | Univ Kansai Medical | Medical tube |
CN101484619A (en) * | 2006-07-05 | 2009-07-15 | 松下电器产业株式会社 | Method and apparatus for producing nanofiber and polymeric web |
US9198749B2 (en) | 2006-10-12 | 2015-12-01 | C. R. Bard, Inc. | Vascular grafts with multiple channels and methods for making |
US9492596B2 (en) | 2006-11-06 | 2016-11-15 | Atrium Medical Corporation | Barrier layer with underlying medical device and one or more reinforcing support structures |
US9622888B2 (en) | 2006-11-16 | 2017-04-18 | W. L. Gore & Associates, Inc. | Stent having flexibly connected adjacent stent elements |
JP4809203B2 (en) * | 2006-12-13 | 2011-11-09 | パナソニック株式会社 | Nonwoven fabric manufacturing apparatus and nonwoven fabric manufacturing method |
TW200848561A (en) * | 2006-12-22 | 2008-12-16 | Body Organ Biomedical Corp | Device for manufacturing fibrils |
ATE481435T1 (en) * | 2007-01-12 | 2010-10-15 | Dow Corning | COMPOSITION CONTAINING SILICONE |
US8546333B2 (en) | 2007-02-01 | 2013-10-01 | Technion Research & Development Foundation Limited | Albumin fibers and fabrics and methods of generating and using same |
US20080208325A1 (en) * | 2007-02-27 | 2008-08-28 | Boston Scientific Scimed, Inc. | Medical articles for long term implantation |
JP2008253297A (en) * | 2007-03-30 | 2008-10-23 | Univ Kansai Medical | Medical tube |
US20090042029A1 (en) * | 2007-04-13 | 2009-02-12 | Drexel University | Polyamide nanofibers and methods thereof |
US7993567B2 (en) * | 2007-06-01 | 2011-08-09 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Method and system for aligning fibers during electrospinning |
US20100070020A1 (en) * | 2008-06-11 | 2010-03-18 | Nanovasc, Inc. | Implantable Medical Device |
US20090018643A1 (en) * | 2007-06-11 | 2009-01-15 | Nanovasc, Inc. | Stents |
US20100331957A1 (en) * | 2007-06-11 | 2010-12-30 | Nanovasc, Inc. | Implantable medical device |
EP2160486A4 (en) * | 2007-06-19 | 2011-09-14 | Ca Nat Research Council | Non-woven mat and method of producing same |
US20090004455A1 (en) * | 2007-06-27 | 2009-01-01 | Philippe Gravagna | Reinforced composite implant |
JP5142607B2 (en) * | 2007-07-03 | 2013-02-13 | 兵庫県 | Cover stent and manufacturing method thereof |
US20090030504A1 (en) * | 2007-07-27 | 2009-01-29 | Boston Scientific Scimed, Inc. | Medical devices comprising porous inorganic fibers for the release of therapeutic agents |
BRPI0817544A2 (en) * | 2007-10-10 | 2017-05-02 | Univ Wake Forest Health Sciences | apparatus for treating damaged spinal cord tissue |
US20090178206A1 (en) * | 2007-11-09 | 2009-07-16 | E.I. Du Pont De Nemours And Company | Solvent stripping process ultilizing an antioxidant |
US9308068B2 (en) | 2007-12-03 | 2016-04-12 | Sofradim Production | Implant for parastomal hernia |
US8926688B2 (en) | 2008-01-11 | 2015-01-06 | W. L. Gore & Assoc. Inc. | Stent having adjacent elements connected by flexible webs |
CA2718897A1 (en) * | 2008-03-17 | 2009-09-17 | The Board Of Regents Of The University Of Texas System | Superfine fiber creating spinneret and uses thereof |
US8252048B2 (en) | 2008-03-19 | 2012-08-28 | Boston Scientific Scimed, Inc. | Drug eluting stent and method of making the same |
US20110082565A1 (en) * | 2008-06-10 | 2011-04-07 | Technion Research & Development | Nonwoven structure and method of fabricating the same |
US9242026B2 (en) * | 2008-06-27 | 2016-01-26 | Sofradim Production | Biosynthetic implant for soft tissue repair |
US8049061B2 (en) * | 2008-09-25 | 2011-11-01 | Abbott Cardiovascular Systems, Inc. | Expandable member formed of a fibrous matrix having hydrogel polymer for intraluminal drug delivery |
US8076529B2 (en) | 2008-09-26 | 2011-12-13 | Abbott Cardiovascular Systems, Inc. | Expandable member formed of a fibrous matrix for intraluminal drug delivery |
US8226603B2 (en) * | 2008-09-25 | 2012-07-24 | Abbott Cardiovascular Systems Inc. | Expandable member having a covering formed of a fibrous matrix for intraluminal drug delivery |
EP2962704A1 (en) | 2008-10-07 | 2016-01-06 | Nanonerve, Inc. | Multilayer fibrous polymer scaffolds, methods of production and methods of use |
CN102216502B (en) * | 2008-10-17 | 2014-05-14 | 迪肯大学 | Electrostatic spinning assembly |
US9427304B2 (en) * | 2008-10-27 | 2016-08-30 | St. Jude Medical, Cardiology Division, Inc. | Multi-layer device with gap for treating a target site and associated method |
US20130268062A1 (en) * | 2012-04-05 | 2013-10-10 | Zeus Industrial Products, Inc. | Composite prosthetic devices |
DK2384375T3 (en) | 2009-01-16 | 2017-10-16 | Zeus Ind Products Inc | ELECTROSPINING PTFE WITH HIGH-VISUAL MATERIALS |
US8262979B2 (en) | 2009-08-07 | 2012-09-11 | Zeus Industrial Products, Inc. | Process of making a prosthetic device from electrospun fibers |
WO2010089955A1 (en) | 2009-02-05 | 2010-08-12 | パナソニック株式会社 | Nanofiber production device and nanofiber production method |
JP2012520761A (en) | 2009-03-19 | 2012-09-10 | イー・エム・デイー・ミリポア・コーポレイシヨン | Removal of microorganisms from fluid data using nanofiber filtration media |
US8346374B2 (en) * | 2009-07-09 | 2013-01-01 | Cardiac Pacemakers, Inc. | Laminate distal lead seal with tissue ingrowth feature |
US20110038910A1 (en) | 2009-08-11 | 2011-02-17 | Atrium Medical Corporation | Anti-infective antimicrobial-containing biomaterials |
FR2949688B1 (en) | 2009-09-04 | 2012-08-24 | Sofradim Production | FABRIC WITH PICOTS COATED WITH A BIORESORBABLE MICROPOROUS LAYER |
DE102009047925A1 (en) | 2009-10-01 | 2011-06-16 | Qualimed Innovative Medizinprodukte Gmbh | Endoluminal tubular stent graft |
EP2314739A1 (en) * | 2009-10-22 | 2011-04-27 | Gyeong-Man Kim | Anti-migration casing for transponders |
US9005604B2 (en) | 2009-12-15 | 2015-04-14 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Aligned and electrospun piezoelectric polymer fiber assembly and scaffold |
EP2519188A4 (en) | 2009-12-31 | 2017-03-22 | Neograft Technologies, Inc. | Graft devices and methods of fabrication |
CZ303024B6 (en) * | 2010-03-05 | 2012-02-29 | Šafár@Václav | Process for producing nanofibers by electrostatic spinning of polymeric solution and apparatus for making the same |
WO2011119536A1 (en) | 2010-03-22 | 2011-09-29 | Abbott Cardiovascular Systems Inc. | Stent delivery system having a fibrous matrix covering with improved stent retention |
KR20130086518A (en) * | 2010-05-27 | 2013-08-02 | 헤모텍 아게 | Coating of endoprostheses with a coating consisting of a tight mesh of polymer fibers |
EP2582868B1 (en) | 2010-06-17 | 2018-03-28 | Washington University | Biomedical patches with aligned fibers |
EP2593141B1 (en) | 2010-07-16 | 2018-07-04 | Atrium Medical Corporation | Composition and methods for altering the rate of hydrolysis of cured oil-based materials |
SG185659A1 (en) | 2010-08-10 | 2012-12-28 | Emd Millipore Corp | Method for retrovirus removal |
CN102782196A (en) | 2010-10-14 | 2012-11-14 | 宙斯工业产品股份有限公司 | Antimicrobial substrate |
EP2646065A4 (en) | 2010-12-05 | 2016-03-23 | Nanonerve Inc | Fibrous polymer scaffolds having diametrically patterned polymer fibers |
KR101187212B1 (en) | 2010-12-30 | 2012-10-02 | 주식회사 엠아이텍 | Method for manufacturing drug eluting stent for benign biliary structure using electrospinning |
EP2667829B1 (en) * | 2011-01-28 | 2021-09-22 | Merit Medical Systems, Inc. | Electrospun ptfe coated stent and method of use |
WO2012109242A2 (en) | 2011-02-07 | 2012-08-16 | Fiberio Technology Corporation | Devices and methods for the production of coaxial microfibers and nanofibers |
DE102011012501A1 (en) * | 2011-02-25 | 2012-08-30 | Phenox Gmbh | Implant with fiber fleece |
FR2972626B1 (en) | 2011-03-16 | 2014-04-11 | Sofradim Production | PROSTHETIC COMPRISING A THREE-DIMENSIONAL KNIT AND ADJUSTED |
US10227568B2 (en) | 2011-03-22 | 2019-03-12 | Nanofiber Solutions, Llc | Fiber scaffolds for use in esophageal prostheses |
CN103459006B (en) | 2011-04-01 | 2016-01-06 | Emd密理博公司 | Composite structure containing nanofiber |
CZ303380B6 (en) | 2011-06-27 | 2012-08-22 | Contipro Biotech S.R.O. | Process for producing materials exhibiting anisotropic properties and composed of nanofibers or microfibers and apparatus for making the same |
FR2977790B1 (en) | 2011-07-13 | 2013-07-19 | Sofradim Production | PROSTHETIC FOR UMBILIC HERNIA |
FR2977789B1 (en) | 2011-07-13 | 2013-07-19 | Sofradim Production | PROSTHETIC FOR UMBILIC HERNIA |
JP5665803B2 (en) * | 2011-07-15 | 2015-02-04 | クック メディカル テクノロジーズ エルエルシーCook Medical Technologies Llc | Method for electrospinning a graft layer |
EP2734261B1 (en) | 2011-07-18 | 2018-02-21 | Mor-Research Applications Ltd. | A device for adjusting the intraocular pressure |
CN102358959B (en) * | 2011-08-16 | 2013-11-06 | 中山大学 | Method and device for preparing electrospinning fiber bracket with three-dimensional structure |
CN102973989A (en) * | 2011-09-05 | 2013-03-20 | 上海市第十人民医院 | Method for preparing surface fiber membrane of cardia stent |
CN102973339A (en) * | 2011-09-05 | 2013-03-20 | 上海市第十人民医院 | Cardia stent with drug coating |
CN102973340A (en) * | 2011-09-05 | 2013-03-20 | 上海市第十人民医院 | Biodegradable cardia support |
WO2013046058A2 (en) | 2011-09-30 | 2013-04-04 | Sofradim Production | Reversible stiffening of light weight mesh |
WO2013078051A1 (en) | 2011-11-21 | 2013-05-30 | Johnson Jed K | Fiber scaffolds for use in tracheal prostheses |
FR2985170B1 (en) | 2011-12-29 | 2014-01-24 | Sofradim Production | PROSTHESIS FOR INGUINAL HERNIA |
FR2985271B1 (en) | 2011-12-29 | 2014-01-24 | Sofradim Production | KNITTED PICOTS |
DE102012008656A1 (en) | 2011-12-29 | 2013-07-04 | Nonwotecc Medical Gmbh | Structure with fibers glued together in places |
WO2013106822A1 (en) | 2012-01-12 | 2013-07-18 | Johnson Jed K | Nanofiber scaffolds for biological structures |
JP6300732B2 (en) | 2012-01-16 | 2018-03-28 | メリット・メディカル・システムズ・インコーポレイテッドMerit Medical Systems,Inc. | Medical device coated with rotating span material and method of manufacturing the same |
AU2013221580A1 (en) * | 2012-02-14 | 2014-08-28 | Neograft Technologies, Inc. | Kink resistant graft devices and related systems and methods |
PL231639B1 (en) | 2012-04-17 | 2019-03-29 | Politechnika Lodzka | Medical material for the reconstruction of blood vessels, a method for producing the medical material and medical material applied to the reconstruction of blood vessels |
US9867880B2 (en) | 2012-06-13 | 2018-01-16 | Atrium Medical Corporation | Cured oil-hydrogel biomaterial compositions for controlled drug delivery |
FR2994185B1 (en) | 2012-08-02 | 2015-07-31 | Sofradim Production | PROCESS FOR THE PREPARATION OF A POROUS CHITOSAN LAYER |
CA2882984A1 (en) * | 2012-08-24 | 2014-02-27 | Boston Scientific Corporation | Device and method for improving brachytherapy |
CN102784015B (en) * | 2012-08-30 | 2015-06-03 | 广州迈普再生医学科技有限公司 | Artificial blood vessel loaded with pseudo-ginseng medicines, and preparation method and application for artificial blood vessel |
US20140081386A1 (en) * | 2012-09-14 | 2014-03-20 | Cook Medical Technologies Llc | Endoluminal prosthesis |
US10507268B2 (en) * | 2012-09-19 | 2019-12-17 | Merit Medical Systems, Inc. | Electrospun material covered medical appliances and methods of manufacture |
IN2015DN02299A (en) | 2012-09-21 | 2015-08-21 | Univ Washington | |
US9198999B2 (en) | 2012-09-21 | 2015-12-01 | Merit Medical Systems, Inc. | Drug-eluting rotational spun coatings and methods of use |
FR2995778B1 (en) | 2012-09-25 | 2015-06-26 | Sofradim Production | ABDOMINAL WALL REINFORCING PROSTHESIS AND METHOD FOR MANUFACTURING THE SAME |
FR2995788B1 (en) | 2012-09-25 | 2014-09-26 | Sofradim Production | HEMOSTATIC PATCH AND PREPARATION METHOD |
FR2995779B1 (en) | 2012-09-25 | 2015-09-25 | Sofradim Production | PROSTHETIC COMPRISING A TREILLIS AND A MEANS OF CONSOLIDATION |
EP2900174B1 (en) | 2012-09-28 | 2017-04-12 | Sofradim Production | Packaging for a hernia repair device |
US10582998B1 (en) * | 2012-10-17 | 2020-03-10 | Medshape, Inc. | Shape memory polymer fabrics |
US9091007B2 (en) * | 2012-12-10 | 2015-07-28 | Taipei Medical University | Electrospinning apparatus with a sideway motion device and a method of using the same |
US8992817B2 (en) * | 2012-12-10 | 2015-03-31 | Abbott Cardiovascular Systems, Inc. | Process of making a medical balloon |
US10154918B2 (en) * | 2012-12-28 | 2018-12-18 | Cook Medical Technologies Llc | Endoluminal prosthesis with fiber matrix |
WO2014159399A1 (en) | 2013-03-13 | 2014-10-02 | Merit Medical Systems, Inc. | Methods, systems, and apparatuses for manufacturing rotational spun appliances |
EP3988278A1 (en) * | 2013-03-13 | 2022-04-27 | Merit Medical Systems, Inc. | Serially deposited fiber materials and associated devices and methods |
US10660645B2 (en) | 2013-03-15 | 2020-05-26 | Embo Medical Limited | Embolization systems |
CN105209678A (en) | 2013-03-15 | 2015-12-30 | 纳米纤维解决方案股份有限公司 | Biocompatible fiber textiles for implantation |
US10675039B2 (en) | 2013-03-15 | 2020-06-09 | Embo Medical Limited | Embolisation systems |
JP6806442B2 (en) | 2013-03-15 | 2021-01-06 | エンボ・メディカル・リミテッド | Embolus formation system |
FR3006581B1 (en) | 2013-06-07 | 2016-07-22 | Sofradim Production | PROSTHESIS BASED ON TEXTILE FOR LAPAROSCOPIC PATHWAY |
FR3006578B1 (en) | 2013-06-07 | 2015-05-29 | Sofradim Production | PROSTHESIS BASED ON TEXTILE FOR LAPAROSCOPIC PATHWAY |
CN103432631B (en) * | 2013-06-26 | 2014-12-31 | 上海大学 | Novel biodegradable vascular stent preparation method |
CN103418023B (en) * | 2013-07-29 | 2014-09-03 | 大连医科大学 | Multilayer composite hemostatic material and preparation method thereof |
WO2015048224A1 (en) * | 2013-09-25 | 2015-04-02 | Johnson Jed K | Fiber scaffolds for use creating implantable structures |
JP2015068986A (en) * | 2013-09-27 | 2015-04-13 | キヤノン株式会社 | Manufacturing method of conductive member for electrophotography |
KR101501383B1 (en) * | 2013-10-30 | 2015-03-10 | 가톨릭대학교 산학협력단 | Nanofiber scaffold with an aligned structure and method thereof |
WO2015074151A1 (en) * | 2013-11-20 | 2015-05-28 | Jayaram Sheshakamal | Method and system for forming composites |
US9814560B2 (en) | 2013-12-05 | 2017-11-14 | W. L. Gore & Associates, Inc. | Tapered implantable device and methods for making such devices |
CA2935128A1 (en) * | 2013-12-27 | 2015-07-02 | Neograft Technologies, Inc. | Artificial graft devices and related systems and methods |
CN115040288A (en) * | 2014-02-21 | 2022-09-13 | 矽瑞奥科技公司 | Vascular graft and method for maintaining patency of vascular graft |
US9675361B2 (en) | 2014-02-28 | 2017-06-13 | Cook Medical Technologies Llc | Coil occlusion device |
EP3000489B1 (en) | 2014-09-24 | 2017-04-05 | Sofradim Production | Method for preparing an anti-adhesion barrier film |
EP3000432B1 (en) | 2014-09-29 | 2022-05-04 | Sofradim Production | Textile-based prosthesis for treatment of inguinal hernia |
EP3000433B1 (en) | 2014-09-29 | 2022-09-21 | Sofradim Production | Device for introducing a prosthesis for hernia treatment into an incision and flexible textile based prosthesis |
CN104383606B (en) * | 2014-10-27 | 2016-02-17 | 北京航空航天大学 | A kind of high-strength high-elasticity intravascular stent and preparation method thereof |
US10299948B2 (en) | 2014-11-26 | 2019-05-28 | W. L. Gore & Associates, Inc. | Balloon expandable endoprosthesis |
EP3029189B1 (en) | 2014-12-05 | 2021-08-11 | Sofradim Production | Prosthetic porous knit, method of making same and hernia prosthesis |
US20160175082A1 (en) * | 2014-12-23 | 2016-06-23 | Novus Scientific Ab | Resorbable medical mesh implant for repair or prevention of parastomal hernia |
EP3059255B1 (en) | 2015-02-17 | 2020-05-13 | Sofradim Production | Method for preparing a chitosan-based matrix comprising a fiber reinforcement member |
WO2016138221A1 (en) | 2015-02-26 | 2016-09-01 | Merit Medical Systems, Inc. | Layered medical appliances and methods |
US11129711B2 (en) | 2015-02-27 | 2021-09-28 | University of Pittsburgh—of the Commonwealth System of Higher Education | Double component mandrel for electrospun stentless, multi-leaflet valve fabrication |
US10583004B2 (en) | 2015-02-27 | 2020-03-10 | University of Pittsburgh — Of the Commonwealth System of Higher Education | Retrievable self-expanding non-thrombogenic low-profile percutaneous atrioventricular valve prosthesis |
FR3033494B1 (en) * | 2015-03-10 | 2017-03-24 | Carmat | TISSUE STENT AND METHOD FOR PRODUCING THE SAME |
CN104713909A (en) * | 2015-04-10 | 2015-06-17 | 湖南农业大学 | Simple method for authenticating fluorine injury of plants |
KR102206959B1 (en) | 2015-04-17 | 2021-01-25 | 이엠디 밀리포어 코포레이션 | Method of purifying a biological material of interest in a sample using nanofiber ultrafiltration membranes operated in tangential flow filtration mode |
EP3085337B1 (en) | 2015-04-24 | 2022-09-14 | Sofradim Production | Prosthesis for supporting a breast structure |
US10166315B2 (en) | 2015-05-04 | 2019-01-01 | Nanofiber Solutions, Inc. | Chitosan-enhanced electrospun fiber compositions |
CN107666882B (en) | 2015-06-05 | 2020-01-10 | W.L.戈尔及同仁股份有限公司 | Hypotonic blood volume implantable prosthesis with tapered portion |
CN107979992B (en) | 2015-06-08 | 2020-05-22 | 科尔尼特视觉有限公司 | Artificial cornea and use thereof |
ES2676072T3 (en) | 2015-06-19 | 2018-07-16 | Sofradim Production | Synthetic prosthesis comprising a knitted fabric and a non-porous film and method of forming it |
CN105113029A (en) * | 2015-09-23 | 2015-12-02 | 厦门大学 | Linear nozzle for electrostatic spinning |
EP3355949B1 (en) * | 2015-10-01 | 2022-04-20 | Xeltis AG | Methods for electrospin coating and laminating of endoluminal prostheses |
WO2017070147A1 (en) | 2015-10-23 | 2017-04-27 | Boston Scientific Scimed, Inc. | Radioactive stents |
EP3370788A4 (en) | 2015-11-02 | 2019-07-31 | Nanofiber Solutions, LLC | Electrospun fibers having contrast agents and methods of making the same |
CN108778703A (en) * | 2016-01-08 | 2018-11-09 | 克拉考公司 | The use of microfibre and/or nanofiber in clothes and footwear |
EP3195830B1 (en) | 2016-01-25 | 2020-11-18 | Sofradim Production | Prosthesis for hernia repair |
US20190046696A1 (en) * | 2016-03-11 | 2019-02-14 | The Johns Hopkins University | Partially degradable stents for controlled reduction of intraocular pressure |
KR101795923B1 (en) * | 2016-04-15 | 2017-11-10 | 연세대학교 산학협력단 | Stent for releasing nano-particle including biodegradable polymer, hydrophilic drug and hydrophobic drug |
US10632228B2 (en) | 2016-05-12 | 2020-04-28 | Acera Surgical, Inc. | Tissue substitute materials and methods for tissue repair |
US10568752B2 (en) | 2016-05-25 | 2020-02-25 | W. L. Gore & Associates, Inc. | Controlled endoprosthesis balloon expansion |
EP3312325B1 (en) | 2016-10-21 | 2021-09-22 | Sofradim Production | Method for forming a mesh having a barbed suture attached thereto and the mesh thus obtained |
CN106319647A (en) * | 2016-10-21 | 2017-01-11 | 上海工程技术大学 | Method for preparing nanofiber aggregate and pretreatment device |
WO2018081554A1 (en) * | 2016-10-27 | 2018-05-03 | North Carolina State University | 3d printing of fibrous structures |
US10898608B2 (en) | 2017-02-02 | 2021-01-26 | Nanofiber Solutions, Llc | Methods of improving bone-soft tissue healing using electrospun fibers |
US10368991B2 (en) * | 2017-02-06 | 2019-08-06 | C. R. Bard, Inc. | Device and associated percutaneous minimally invasive method for creating a venous valve |
EP3398554A1 (en) | 2017-05-02 | 2018-11-07 | Sofradim Production | Prosthesis for inguinal hernia repair |
GB201708025D0 (en) * | 2017-05-18 | 2017-07-05 | Clearstream Tech Ltd | A laminate membrane, an implant comprising the laminate membrane and a method of manufacturing the same |
TW201904527A (en) * | 2017-06-23 | 2019-02-01 | 鴻海精密工業股份有限公司 | Artificial blood vessel and method for making the same |
EP3427764A1 (en) * | 2017-07-12 | 2019-01-16 | Université de Technologie de Compiègne | Fibrous polymer material comprising fibroin and polymer scaffolds comprising thereof |
WO2019049085A1 (en) | 2017-09-08 | 2019-03-14 | Board Of Regents Of The University Of Texas System | Mechanoluminescence polymer doped fabrics and methods |
NL2019763B1 (en) * | 2017-10-19 | 2019-04-29 | Innovative Mechanical Engineering Tech B V | Electro hydrodynamic production method and system |
CN112203616A (en) * | 2017-10-30 | 2021-01-08 | 安多拉米诺科学公司 | Expandable sealing skirt technique for leak-proof endovascular prosthesis |
US11174570B2 (en) | 2018-02-05 | 2021-11-16 | Fermi Research Alliance, Llc | Methods and systems for electrospinning using low power voltage converter |
GB2573092A (en) * | 2018-03-02 | 2019-10-30 | The Electrospinning Company Ltd | Porous scaffold for the delivery of therapeutic agents |
CN110512292B (en) * | 2018-05-21 | 2023-02-17 | 武汉纺织大学 | Radial electrospinning nozzle based on rectangular blades |
CZ309078B6 (en) | 2018-05-28 | 2022-01-19 | Contipro A.S. | Device and method of producing nano- and / or microfibrous layers with increased thickness uniformity |
CN108939267B (en) * | 2018-05-28 | 2021-04-16 | 苏州大学 | Controlled drug release device and method |
MX2020013230A (en) | 2018-06-05 | 2021-02-22 | Corneat Vision Ltd | A synthetic ophthalmic graft patch. |
CN109248340B (en) * | 2018-09-18 | 2021-04-23 | 武汉纺织大学 | Preparation method of fiber-based artificial blood vessel |
EP3653171A1 (en) | 2018-11-16 | 2020-05-20 | Sofradim Production | Implants suitable for soft tissue repair |
TW202031958A (en) * | 2018-12-05 | 2020-09-01 | 奧地利商蘭仁股份有限公司 | Method and device for producing tubular cellulosic spunbonded nonwoven fabrics |
DE102018131269B4 (en) | 2018-12-07 | 2021-08-05 | Acandis Gmbh | Medical device for insertion into a hollow body organ and manufacturing process |
US11576927B2 (en) | 2018-12-11 | 2023-02-14 | Nanofiber Solutions, Llc | Methods of treating chronic wounds using electrospun fibers |
WO2020165906A1 (en) * | 2019-02-14 | 2020-08-20 | Technion Research & Development Foundation Limited | Composition, drug delivery device and method for local delivery of an active agent |
US11427937B2 (en) | 2019-02-20 | 2022-08-30 | The Board Of Regents Of The University Of Texas System | Handheld/portable apparatus for the production of microfibers, submicron fibers and nanofibers |
CN110067080B (en) * | 2019-03-07 | 2021-05-25 | 江苏大学 | Janus infrared radiation film for human body heat preservation and preparation method thereof |
CN109908401A (en) * | 2019-03-11 | 2019-06-21 | 武汉杨森生物技术有限公司 | A kind of production method of artificial blood vessel and products thereof for promoting endothelial cell to seek connections with |
CN110215540B (en) * | 2019-04-09 | 2021-07-27 | 盐城工业职业技术学院 | Silk fibroin/polymer based tubular stent with three-dimensional ordered and disordered double-network structure and preparation and use methods thereof |
EP3958787A1 (en) | 2019-04-25 | 2022-03-02 | Corneat Vision Ltd. | Keratoprosthesis devices and kits and surgical methods of their use |
WO2020243684A1 (en) * | 2019-05-30 | 2020-12-03 | Skinner Jack L | Device for polymer materials fabrication using gas flow and electrostatic fields |
CN110141760B (en) * | 2019-06-05 | 2021-10-08 | 山东百多安医疗器械股份有限公司 | Centrum forming expansion balloon with drug loaded on surface and preparation method thereof |
DE102019121562B4 (en) | 2019-08-09 | 2024-01-11 | Acandis Gmbh | Medical device for treating aneurysms |
DE102019121559A1 (en) * | 2019-08-09 | 2021-02-11 | Acandis Gmbh | Medical device for insertion into a hollow body organ and method for producing a medical device |
US20220313872A1 (en) | 2019-08-12 | 2022-10-06 | Corneat Vision Ltd | Gingival graft |
JPWO2021044858A1 (en) * | 2019-09-04 | 2021-03-11 | ||
CN110743033B (en) * | 2019-10-23 | 2021-12-28 | 辽宁燕阳医疗设备有限公司 | Medical dressing |
TWI749395B (en) * | 2019-11-08 | 2021-12-11 | 高鼎精密材料股份有限公司 | Method for fabricating polymer fiber tubular structure with high patency rate |
DE102019135502B4 (en) * | 2019-12-20 | 2022-07-14 | Acandis Gmbh | Medical set, medical system and covering device for the treatment of aneurysms |
CN111139541B (en) * | 2020-03-10 | 2023-06-30 | 苏州大学 | Stirring type large-batch free liquid level electrostatic spinning device and method |
CN113069674B (en) * | 2020-09-30 | 2023-02-28 | 普利瑞医疗科技(苏州)有限公司 | Medical drug stent |
CN114176597A (en) * | 2021-12-17 | 2022-03-15 | 广东思谷智能技术有限公司 | All-electric spinning high-air-permeability high-hydrophobicity friction nano sensor and preparation method thereof |
WO2023161945A1 (en) | 2022-02-27 | 2023-08-31 | Corneat Vision Ltd. | Implantable sensor |
Family Cites Families (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2491889A (en) * | 1942-01-21 | 1949-12-20 | Owens Corning Fiberglass Corp | Production of coated glass and the like products |
US3280229A (en) * | 1963-01-15 | 1966-10-18 | Kendall & Co | Process and apparatus for producing patterned non-woven fabrics |
CH472219A (en) * | 1963-06-15 | 1969-05-15 | Spofa Vereinigte Pharma Werke | Highly porous collagen tissue blood vessel prosthesis and method for producing the same |
US3625745A (en) | 1970-03-18 | 1971-12-07 | Gen Electric | Antithrombogenic article and process |
US3688317A (en) | 1970-08-25 | 1972-09-05 | Sutures Inc | Vascular prosthetic |
US3860369A (en) * | 1972-11-02 | 1975-01-14 | Du Pont | Apparatus for making non-woven fibrous sheet |
GB1527592A (en) | 1974-08-05 | 1978-10-04 | Ici Ltd | Wound dressing |
FR2382688A1 (en) | 1977-03-04 | 1978-09-29 | Oreal | HARDNESS MEASURING DEVICE |
EP0005035B1 (en) * | 1978-04-19 | 1981-09-23 | Imperial Chemical Industries Plc | A method of preparing a tubular product by electrostatic spinning |
US4223101A (en) | 1978-07-17 | 1980-09-16 | Inmont Corporation | Method of producing fibrous structure |
EP0009941B2 (en) * | 1978-10-10 | 1987-05-27 | Imperial Chemical Industries Plc | Production of electrostatically spun products |
EP0011437B1 (en) | 1978-11-20 | 1983-06-22 | Imperial Chemical Industries Plc | A process for setting a product comprising electrostatically spun fibres, and products prepared according to this process |
FI70586C (en) | 1979-05-03 | 1986-09-24 | Le I Textilnoi | POROEST FYLLMEDELINNEHAOLLANDE REACTIVE MATERIAL VID OEPPNA CELER OCH FOERFARANDE FOER FRAMSTAELLNING AV DETTA |
FR2511014B1 (en) * | 1981-08-10 | 1987-02-06 | Ethicon Inc | PROCESS FOR THE PREPARATION OF A POLYURETHANE RESIN SUITABLE FOR ELECTROSTATIC SPINNING |
US4475972A (en) | 1981-10-01 | 1984-10-09 | Ontario Research Foundation | Implantable material |
GB2142870B (en) | 1983-07-06 | 1986-06-04 | Ethicon Inc | Manufacturing vascular prostheses by electrostatic spinning |
US4759757A (en) * | 1984-04-18 | 1988-07-26 | Corvita Corporation | Cardiovascular graft and method of forming same |
US4657793A (en) | 1984-07-16 | 1987-04-14 | Ethicon, Inc. | Fibrous structures |
US5679967A (en) * | 1985-01-20 | 1997-10-21 | Chip Express (Israel) Ltd. | Customizable three metal layer gate array devices |
US4798606A (en) * | 1985-02-26 | 1989-01-17 | Corvita Corporation | Reinforcing structure for cardiovascular graft |
US4880002A (en) * | 1985-05-30 | 1989-11-14 | Corvita Corporation | Stretchable porous sutures |
GB2181207B (en) | 1985-10-04 | 1990-05-23 | Ethicon Inc | Improvements in electrostatically produced structures and methods of manufacturing thereof |
US4738740A (en) * | 1985-11-21 | 1988-04-19 | Corvita Corporation | Method of forming implantable vascular grafts |
US4739013A (en) * | 1985-12-19 | 1988-04-19 | Corvita Corporation | Polyurethanes |
US4743252A (en) | 1986-01-13 | 1988-05-10 | Corvita Corporation | Composite grafts |
GB2189738B (en) * | 1986-03-24 | 1989-11-15 | Ethicon Inc | Apparatus for producing fibrous structures electrostatically |
GB8617527D0 (en) | 1986-07-17 | 1986-08-28 | Ici Plc | Spraying process |
US4802145A (en) | 1986-08-01 | 1989-01-31 | Amoco Corporation | Method and apparatus for determining cement conditions |
US5084085A (en) | 1986-08-20 | 1992-01-28 | Fmc Corporation | Herbicidal aryloxyphenyltriazolinones and related compounds |
US4769030A (en) | 1987-04-28 | 1988-09-06 | Corvita Corporation | Monomer and use thereof in crack prevention of implanted prostheses |
US4872455A (en) * | 1987-11-25 | 1989-10-10 | Corvita Corporation | Anastomosis trimming device and method of using the same |
US4997600A (en) * | 1988-05-24 | 1991-03-05 | Mitsubishi Monsanto Chemical Company, Ltd. | Process for preparation of thermoplastic resin sheets |
US4965110A (en) * | 1988-06-20 | 1990-10-23 | Ethicon, Inc. | Electrostatically produced structures and methods of manufacturing |
US5226913A (en) | 1988-09-01 | 1993-07-13 | Corvita Corporation | Method of making a radially expandable prosthesis |
US5092877A (en) * | 1988-09-01 | 1992-03-03 | Corvita Corporation | Radially expandable endoprosthesis |
US5019090A (en) | 1988-09-01 | 1991-05-28 | Corvita Corporation | Radially expandable endoprosthesis and the like |
US4904174A (en) * | 1988-09-15 | 1990-02-27 | Peter Moosmayer | Apparatus for electrically charging meltblown webs (B-001) |
US5024671A (en) * | 1988-09-19 | 1991-06-18 | Baxter International Inc. | Microporous vascular graft |
US5024789A (en) * | 1988-10-13 | 1991-06-18 | Ethicon, Inc. | Method and apparatus for manufacturing electrostatically spun structure |
US5298255A (en) | 1988-10-28 | 1994-03-29 | Terumo Kabushiki Kaisha | Antithrombic medical material, artificial internal organ, and method for production of antithrombic medical material |
US4905367A (en) * | 1988-11-08 | 1990-03-06 | Corvita Corporation | Manufacture of stretchable porous sutures |
US4990158A (en) | 1989-05-10 | 1991-02-05 | United States Surgical Corporation | Synthetic semiabsorbable tubular prosthesis |
US5084065A (en) * | 1989-07-10 | 1992-01-28 | Corvita Corporation | Reinforced graft assembly |
US6004346A (en) | 1990-02-28 | 1999-12-21 | Medtronic, Inc. | Intralumenal drug eluting prosthesis |
US5545208A (en) * | 1990-02-28 | 1996-08-13 | Medtronic, Inc. | Intralumenal drug eluting prosthesis |
CA2038605C (en) | 1990-06-15 | 2000-06-27 | Leonard Pinchuk | Crack-resistant polycarbonate urethane polymer prostheses and the like |
US5147725A (en) | 1990-07-03 | 1992-09-15 | Corvita Corporation | Method for bonding silicone rubber and polyurethane materials and articles manufactured thereby |
US6117425A (en) * | 1990-11-27 | 2000-09-12 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, method of their production and use |
US5116360A (en) * | 1990-12-27 | 1992-05-26 | Corvita Corporation | Mesh composite graft |
GB9115276D0 (en) | 1991-07-15 | 1991-08-28 | Unilever Plc | Skin treatment system |
US5376117A (en) | 1991-10-25 | 1994-12-27 | Corvita Corporation | Breast prostheses |
US5599352A (en) | 1992-03-19 | 1997-02-04 | Medtronic, Inc. | Method of making a drug eluting stent |
US5383928A (en) | 1992-06-10 | 1995-01-24 | Emory University | Stent sheath for local drug delivery |
BE1006440A3 (en) * | 1992-12-21 | 1994-08-30 | Dereume Jean Pierre Georges Em | Luminal endoprosthesis AND METHOD OF PREPARATION. |
US5419760A (en) | 1993-01-08 | 1995-05-30 | Pdt Systems, Inc. | Medicament dispensing stent for prevention of restenosis of a blood vessel |
EP0623941B1 (en) * | 1993-03-09 | 1997-08-06 | Hoechst Celanese Corporation | Polymer electrets with improved charge stability |
US5334201A (en) * | 1993-03-12 | 1994-08-02 | Cowan Kevin P | Permanent stent made of a cross linkable material |
US5383922A (en) * | 1993-03-15 | 1995-01-24 | Medtronic, Inc. | RF lead fixation and implantable lead |
JPH08507715A (en) | 1993-03-18 | 1996-08-20 | シーダーズ サイナイ メディカル センター | Drug-inducing and releasable polymeric coatings for bioartificial components |
US5464650A (en) * | 1993-04-26 | 1995-11-07 | Medtronic, Inc. | Intravascular stent and method |
US5824048A (en) | 1993-04-26 | 1998-10-20 | Medtronic, Inc. | Method for delivering a therapeutic substance to a body lumen |
US5360397A (en) | 1993-07-02 | 1994-11-01 | Corvita Corporation | Hemodiaylsis catheter and catheter assembly |
DE4327595A1 (en) * | 1993-08-17 | 1995-02-23 | Hoechst Ag | Compositions with improved electrostatic properties containing aromatic polyamides, molded articles made therefrom and their use and process for their production |
US5632772A (en) * | 1993-10-21 | 1997-05-27 | Corvita Corporation | Expandable supportive branched endoluminal grafts |
US5855598A (en) | 1993-10-21 | 1999-01-05 | Corvita Corporation | Expandable supportive branched endoluminal grafts |
US5723004A (en) * | 1993-10-21 | 1998-03-03 | Corvita Corporation | Expandable supportive endoluminal grafts |
US5639278A (en) | 1993-10-21 | 1997-06-17 | Corvita Corporation | Expandable supportive bifurcated endoluminal grafts |
US5549663A (en) * | 1994-03-09 | 1996-08-27 | Cordis Corporation | Endoprosthesis having graft member and exposed welded end junctions, method and procedure |
US5415664A (en) * | 1994-03-30 | 1995-05-16 | Corvita Corporation | Method and apparatus for introducing a stent or a stent-graft |
US6001123A (en) * | 1994-04-01 | 1999-12-14 | Gore Enterprise Holdings Inc. | Folding self-expandable intravascular stent-graft |
US5629077A (en) | 1994-06-27 | 1997-05-13 | Advanced Cardiovascular Systems, Inc. | Biodegradable mesh and film stent |
EP0689805B1 (en) | 1994-06-27 | 2003-05-28 | Corvita Corporation | Bistable luminal graft endoprostheses |
DE9414040U1 (en) * | 1994-08-30 | 1995-01-19 | Hoechst Ag | Nonwovens made from electret fiber blends with improved charge stability |
WO1996011720A1 (en) | 1994-10-17 | 1996-04-25 | Kabushikikaisha Igaki Iryo Sekkei | Drug-releasing stent |
US5637113A (en) * | 1994-12-13 | 1997-06-10 | Advanced Cardiovascular Systems, Inc. | Polymer film for wrapping a stent structure |
US5755722A (en) * | 1994-12-22 | 1998-05-26 | Boston Scientific Corporation | Stent placement device with medication dispenser and method |
US5575818A (en) | 1995-02-14 | 1996-11-19 | Corvita Corporation | Endovascular stent with locking ring |
EP0810845A2 (en) | 1995-02-22 | 1997-12-10 | Menlo Care Inc. | Covered expanding mesh stent |
US6579314B1 (en) * | 1995-03-10 | 2003-06-17 | C.R. Bard, Inc. | Covered stent with encapsulated ends |
BE1009278A3 (en) * | 1995-04-12 | 1997-01-07 | Corvita Europ | Guardian self-expandable medical device introduced in cavite body, and medical device with a stake as. |
BE1009277A3 (en) | 1995-04-12 | 1997-01-07 | Corvita Europ | Guardian self-expandable medical device introduced in cavite body, and method of preparation. |
US5700269A (en) * | 1995-06-06 | 1997-12-23 | Corvita Corporation | Endoluminal prosthesis deployment device for use with prostheses of variable length and having retraction ability |
CA2178541C (en) | 1995-06-07 | 2009-11-24 | Neal E. Fearnot | Implantable medical device |
US5609629A (en) * | 1995-06-07 | 1997-03-11 | Med Institute, Inc. | Coated implantable medical device |
EP0871880A1 (en) | 1995-06-08 | 1998-10-21 | Instituut voor Milieu- en Agritechniek (IMAG-DLO) | Method for determining the degree of hardening of a material |
US5627368A (en) | 1995-07-05 | 1997-05-06 | Gas Research Institute | Four-detector formation-density tool for use in cased and open holes |
US5628788A (en) | 1995-11-07 | 1997-05-13 | Corvita Corporation | Self-expanding endoluminal stent-graft |
US5800512A (en) | 1996-01-22 | 1998-09-01 | Meadox Medicals, Inc. | PTFE vascular graft |
US5749921A (en) | 1996-02-20 | 1998-05-12 | Medtronic, Inc. | Apparatus and methods for compression of endoluminal prostheses |
CA2199890C (en) | 1996-03-26 | 2002-02-05 | Leonard Pinchuk | Stents and stent-grafts having enhanced hoop strength and methods of making the same |
US6252129B1 (en) | 1996-07-23 | 2001-06-26 | Electrosols, Ltd. | Dispensing device and method for forming material |
US5741331A (en) | 1996-07-29 | 1998-04-21 | Corvita Corporation | Biostable elastomeric polymers having quaternary carbons |
US5797887A (en) * | 1996-08-27 | 1998-08-25 | Novovasc Llc | Medical device with a surface adapted for exposure to a blood stream which is coated with a polymer containing a nitrosyl-containing organo-metallic compound which releases nitric oxide from the coating to mediate platelet aggregation |
SE509834C2 (en) | 1996-09-09 | 1999-03-15 | Bandak As | Filter element for pressure filter |
IL119809A (en) * | 1996-12-11 | 2001-06-14 | Nicast Ltd | Device for manufacture of composite filtering material and method of its manufacture |
US5980972A (en) * | 1996-12-20 | 1999-11-09 | Schneider (Usa) Inc | Method of applying drug-release coatings |
US5980551A (en) | 1997-02-07 | 1999-11-09 | Endovasc Ltd., Inc. | Composition and method for making a biodegradable drug delivery stent |
US5843172A (en) | 1997-04-15 | 1998-12-01 | Advanced Cardiovascular Systems, Inc. | Porous medicated stent |
US6371982B2 (en) | 1997-10-09 | 2002-04-16 | St. Jude Medical Cardiovascular Group, Inc. | Graft structures with compliance gradients |
US6106913A (en) | 1997-10-10 | 2000-08-22 | Quantum Group, Inc | Fibrous structures containing nanofibrils and other textile fibers |
US5938697A (en) | 1998-03-04 | 1999-08-17 | Scimed Life Systems, Inc. | Stent having variable properties |
US6019789A (en) * | 1998-04-01 | 2000-02-01 | Quanam Medical Corporation | Expandable unit cell and intraluminal stent |
US6013099A (en) | 1998-04-29 | 2000-01-11 | Medtronic, Inc. | Medical device for delivering a water-insoluble therapeutic salt or substance |
US6265333B1 (en) * | 1998-06-02 | 2001-07-24 | Board Of Regents, University Of Nebraska-Lincoln | Delamination resistant composites prepared by small diameter fiber reinforcement at ply interfaces |
US20020081732A1 (en) * | 2000-10-18 | 2002-06-27 | Bowlin Gary L. | Electroprocessing in drug delivery and cell encapsulation |
US6306424B1 (en) * | 1999-06-30 | 2001-10-23 | Ethicon, Inc. | Foam composite for the repair or regeneration of tissue |
US6682004B2 (en) | 1999-08-18 | 2004-01-27 | The Procter & Gamble Company | Electrostatic spray device |
US6270793B1 (en) | 1999-09-13 | 2001-08-07 | Keraplast Technologies, Ltd. | Absorbent keratin wound dressing |
US20020084178A1 (en) * | 2000-12-19 | 2002-07-04 | Nicast Corporation Ltd. | Method and apparatus for manufacturing polymer fiber shells via electrospinning |
-
2001
- 2001-10-19 US US09/982,017 patent/US20020084178A1/en not_active Abandoned
- 2001-12-17 WO PCT/IL2001/001172 patent/WO2002049536A2/en active Application Filing
- 2001-12-17 WO PCT/IL2001/001171 patent/WO2002049535A2/en active Application Filing
- 2001-12-17 CN CNA018227031A patent/CN1635861A/en active Pending
- 2001-12-17 JP JP2002551015A patent/JP2005507464A/en active Pending
- 2001-12-17 JP JP2002550881A patent/JP2004532665A/en active Pending
- 2001-12-17 US US10/433,621 patent/US7112293B2/en not_active Expired - Fee Related
- 2001-12-17 CA CA002432156A patent/CA2432156A1/en not_active Abandoned
- 2001-12-17 DE DE60141710T patent/DE60141710D1/en not_active Expired - Lifetime
- 2001-12-17 AU AU2002216342A patent/AU2002216342A1/en not_active Abandoned
- 2001-12-17 WO PCT/IL2001/001168 patent/WO2002049678A2/en active Application Filing
- 2001-12-17 MX MXPA03005552A patent/MXPA03005552A/en unknown
- 2001-12-17 DE DE60141607T patent/DE60141607D1/en not_active Expired - Lifetime
- 2001-12-17 AT AT01271232T patent/ATE460903T1/en not_active IP Right Cessation
- 2001-12-17 CN CNA018226671A patent/CN1599582A/en active Pending
- 2001-12-17 AU AU2002222494A patent/AU2002222494A8/en not_active Abandoned
- 2001-12-17 US US10/433,622 patent/US7115220B2/en not_active Expired - Fee Related
- 2001-12-17 MX MXPA03005553A patent/MXPA03005553A/en unknown
- 2001-12-17 MX MXPA03005551A patent/MXPA03005551A/en unknown
- 2001-12-17 IL IL15651201A patent/IL156512A0/en unknown
- 2001-12-17 IL IL15651301A patent/IL156513A0/en active IP Right Grant
- 2001-12-17 CA CA2432164A patent/CA2432164C/en not_active Expired - Fee Related
- 2001-12-17 IL IL15651401A patent/IL156514A0/en unknown
- 2001-12-17 JP JP2002550882A patent/JP4145143B2/en not_active Expired - Fee Related
- 2001-12-17 CN CNA018226612A patent/CN1489513A/en active Pending
- 2001-12-17 EP EP01271184A patent/EP1578306A2/en not_active Withdrawn
- 2001-12-17 AU AU2002222494A patent/AU2002222494A1/en not_active Abandoned
- 2001-12-17 EP EP01271185A patent/EP1353606B1/en not_active Expired - Lifetime
- 2001-12-17 AT AT01271185T patent/ATE462371T1/en not_active IP Right Cessation
- 2001-12-17 CA CA002432159A patent/CA2432159A1/en not_active Abandoned
- 2001-12-17 AU AU2002216340A patent/AU2002216340A1/en not_active Abandoned
- 2001-12-17 EP EP01271232A patent/EP1355677B1/en not_active Expired - Lifetime
-
2002
- 2002-03-19 US US10/471,277 patent/US7244116B2/en not_active Expired - Fee Related
- 2002-03-19 US US10/471,276 patent/US7276271B2/en not_active Expired - Fee Related
-
2003
- 2003-06-18 IL IL156513A patent/IL156513A/en not_active IP Right Cessation
- 2003-06-18 IL IL156514A patent/IL156514A/en not_active IP Right Cessation
-
2006
- 2006-01-04 HK HK06100173.3A patent/HK1080347A1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20040030377A1 (en) | Medicated polymer-coated stent assembly | |
CA2432159A1 (en) | Medicated polymer-coated stent assembly | |
US20070031607A1 (en) | Method and apparatus for coating medical implants | |
CA2541520A1 (en) | Method and apparatus for coating medical implants | |
JP2008540022A (en) | Implantable charged medical device | |
US20180064916A1 (en) | Coated medical device | |
EP1500407B1 (en) | Drug release stent coating process | |
JP2002531183A (en) | Polymer coatings for controlled delivery of active agents | |
CN102885664A (en) | Drug-delivery endovascular stent and method of use | |
CN101663054B (en) | Drug-delivery endovascular stent and method of use | |
JP5227326B2 (en) | Stent having a drug eluting coating | |
JP2010508901A5 (en) | ||
US20210379252A1 (en) | Tubular nonwoven structure as active agent carrier for the atraumatic treatment of hollow organs, and a process for producing the same | |
JP5142607B2 (en) | Cover stent and manufacturing method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |